WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with Docetaxel therapy is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive Docetaxel as a single agent at a dose of 100 mg/m 2 [see Warnings and Precautions (5.1)]. Avoid the use of Docetaxel in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN.
Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 × ULN also had a higher rate of febrile neutropenia.
Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of Docetaxel [see Warnings and Precautions (5.2)]. Do not administer Docetaxel to patients with neutrophil counts of <1500 cells/mm 3. Monitor blood counts frequently as neutropenia may be severe and result in infection [see Warnings and Precautions (5.3)].
Do not administer Docetaxel to patients who have a history of severe hypersensitivity reactions to Docetaxel or to other drugs formulated with polysorbate 80 [see Contraindications (4)]. Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the Docetaxel infusion and administration of appropriate therapy [see Warnings and Precautions (5.5)].
Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions (5.6)].
WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION See full prescribing information for complete boxed warning. Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving Docetaxel at 100 mg/m 2 (5.1) Avoid use of Docetaxel if bilirubin > ULN, or if AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN.
LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle (5.2) Do not administer Docetaxel to patients with neutrophil counts <1500 cells/mm 3. Obtain frequent blood counts to monitor for neutropenia (4, 5.3) Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication.
Severe reactions require immediate discontinuation of docetaxel and administration of appropriate therapy (5.5) Contraindicated if history of severe hypersensitivity reactions to Docetaxel or to drugs formulated with polysorbate 80 (4) Severe fluid retention may occur despite dexamethasone (5.6)
Use: Labeled indications
- Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC
- Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC
- Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer
- Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction
- Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Docetaxel is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer (1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
Docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Contraindications
4 CONTRAINDICATIONS Docetaxel is contraindicated in patients with: neutrophil counts of <1500 cells/mm 3 [see Warnings and Precautions (5.3)]. a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80. Severe reactions, including anaphylaxis, have occurred [see Warnings and Precautions (5.5)]. Hypersensitivity to docetaxel or polysorbate 80 (4) Neutrophil counts of <1500 cells/mm 3 (4)
US FDA labelDosing: Adult
- For all indications, toxicities may warrant dosage adjustments [see Dosage and Administration (2.7)]. Administer in a facility equipped to manage possible complications (e.g., anaphylaxis). Administer in a facility equipped to manage possible complications (e.g., anaphylaxis). Administer intravenously (IV) over 1 hr every 3 weeks. PVC equipment is not recommended. Use only a 21 gauge needle to withdraw Docetaxel from the vial. BC locally advanced or metastatic: 60 mg/m 2 to 100 mg/m 2 single agent (2.1)
- BC adjuvant: 75 mg/m 2 administered 1 hour after doxorubicin 50 mg/m 2 and cyclophosphamide 500 mg/m 2 every 3 weeks for 6 cycles (2.1)
- NSCLC: after platinum therapy failure: 75 mg/m 2 single agent (2.2)
- NSCLC: chemotherapy naive: 75 mg/m 2 followed by cisplatin 75 mg/m 2 (2.2)
- HRPC: 75 mg/m 2 with 5 mg prednisone twice a day continuously (2.3)
- GC: 75 mg/m 2 followed by cisplatin 75 mg/m 2 (both on day 1 only) followed by fluorouracil 750 mg/m 2 per day as a 24-hr IV (days 1–5), starting at end of cisplatin infusion (2.4)
- SCCHN: 75 mg/m 2 followed by cisplatin 75 mg/m 2 IV (day 1), followed by fluorouracil 750 mg/m 2 per day as a 24-hr IV (days 1–5), starting at end of cisplatin infusion; for 4 cycles (2.5)
- SCCHN: 75 mg/m 2 followed by cisplatin 100 mg/m 2 IV (day 1), followed by fluorouracil 1000 mg/m 2 per day as a 24-hr IV (days 1–4); for 3 cycles (2.5)
- For …
2.1 Breast Cancer
2.1 Breast Cancer For locally advanced or metastatic breast cancer after failure of prior chemotherapy, the recommended dose of docetaxel is 60 mg/m 2 to 100 mg/m 2 administered intravenously over 1 hour every 3 weeks. For the adjuvant treatment of operable node-positive breast cancer, the recommended docetaxel dose is 75 mg/m 2 administered 1 hour after doxorubicin 50 mg/m 2 and cyclophosphamide 500 mg/m 2 every 3 weeks for 6 courses.
Prophylactic G-CSF may be used to mitigate the risk of hematological toxicities [see Dosage and Administration (2.7)].
2.2 Non-small Cell Lung Cancer
2.2 Non-small Cell Lung Cancer For treatment after failure of prior platinum-based chemotherapy, docetaxel was evaluated as monotherapy, and the recommended dose is 75 mg/m 2 administered intravenously over 1 hour every 3 weeks. A dose of 100 mg/m 2 in patients previously treated with chemotherapy was associated with increased hematologic toxicity, infection, and treatment-related mortality in randomized controlled trials [see Boxed Warning, Dosage and Administration (2.7), Warnings and Precautions (5), Clinical Studies (14)].
For chemotherapy-naive patients, docetaxel was evaluated in combination with cisplatin. The recommended dose of docetaxel is 75 mg/m 2 administered intravenously over 1 hour immediately followed by cisplatin 75 mg/m 2 over 30–60 minutes every 3 weeks [see Dosage and Administration (2.7)].
2.3 Prostate Cancer
2.3 Prostate Cancer For metastatic castration-resistant prostate cancer, the recommended dose of docetaxel is 75 mg/m 2 every 3 weeks as a 1 hour intravenous infusion. Prednisone 5 mg orally twice daily is administered continuously [see Dosage and Administration (2.7)].
2.4 Gastric Adenocarcinoma
2.4 Gastric Adenocarcinoma For gastric adenocarcinoma, the recommended dose of docetaxel is 75 mg/m 2 as a 1 hour intravenous infusion, followed by cisplatin 75 mg/m 2, as a 1 to 3 hour intravenous infusion (both on day 1 only), followed by fluorouracil 750 mg/m 2 per day given as a 24-hour continuous intravenous infusion for 5 days, starting at the end of the cisplatin infusion. Treatment is repeated every three weeks.
Patients must receive premedication with antiemetics and appropriate hydration for cisplatin administration [see Dosage and Administration (2.7)].
2.5 Head and Neck Cancer
2.5 Head and Neck Cancer Patients must receive premedication with antiemetics, and appropriate hydration (prior to and after cisplatin administration). Prophylaxis for neutropenic infections should be administered. All patients treated on the docetaxel containing arms of the TAX323 and TAX324 studies received prophylactic antibiotics.
Induction Chemotherapy Followed by Radiotherapy (TAX323) For the induction treatment of locally advanced inoperable SCCHN, the recommended dose of docetaxel is 75 mg/m 2 as a 1 hour intravenous infusion followed by cisplatin 75 mg/m 2 intravenously over 1 hour, on day one, followed by fluorouracil as a continuous intravenous infusion at 750 mg/m 2 per day for five days. This regimen is administered every 3 weeks for 4 cycles.
Following chemotherapy, patients should receive radiotherapy [see Dosage and Administration (2.7)]. Induction Chemotherapy Followed by Chemoradiotherapy (TAX324) For the induction treatment of patients with locally advanced (unresectable, low surgical cure, or organ preservation) SCCHN, the recommended dose of docetaxel is 75 mg/m 2 as a 1 hour intravenous infusion on day 1, followed by cisplatin 100 mg/m 2 administered as a 30-minute to 3 hour infusion, followed by fluorouracil 1000 mg/m 2 /day as a continuous infusion from day 1 to day 4.
This regimen is administered every 3 weeks for 3 cycles. Following chemotherapy, patients should receive chemoradiotherapy [see Dosage and Administration (2.7)].
2.6 Premedication Regimen
2.6 Premedication Regimen All patients should be premedicated with oral corticosteroids (see below for prostate cancer) such as dexamethasone 16 mg per day (e.g., 8 mg twice daily) for 3 days starting 1 day prior to docetaxel administration in order to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions [see Boxed Warning, Warnings and Precautions (5.5)]. For metastatic castration-resistant prostate cancer, given the concurrent use of prednisone, the recommended premedication regimen is oral dexamethasone 8 mg at 12 hours, 3 hours, and 1 hour before the docetaxel infusion [see Warnings and Precautions (5.5)].
2.7 Dosage Adjustments during Treatment Breast Cancer
2.7 Dosage Adjustments during Treatment Breast Cancer Patients who are dosed initially at 100 mg/m 2 and who experience either febrile neutropenia, neutrophils <500 cells/mm 3 for more than 1 week, or severe or cumulative cutaneous reactions during docetaxel therapy should have the dosage adjusted from 100 mg/m 2 to 75 mg/m 2. If the patient continues to experience these reactions, the dosage should either be decreased from 75 mg/m 2 to 55 mg/m 2 or the treatment should be discontinued.
Conversely, patients who are dosed initially at 60 mg/m 2 and who do not experience febrile neutropenia, neutrophils <500 cells/mm 3 for more than 1 week, severe or cumulative cutaneous reactions, or severe peripheral neuropathy during docetaxel therapy may tolerate higher doses. Patients who develop ≥grade 3 peripheral neuropathy should have docetaxel treatment discontinued entirely.
Combination Therapy with Docetaxel in the Adjuvant Treatment of Breast Cancer Docetaxel in combination with doxorubicin and cyclophosphamide should be administered when the neutrophil count is ≥1,500 cells/mm 3. Patients who experience febrile neutropenia should receive G-CSF in all subsequent cycles. Patients who continue to experience this reaction should remain on G-CSF and have their docetaxel dose reduced to 60 mg/m 2.
Patients who experience grade 3 or 4 stomatitis should have their docetaxel dose decreased to 60 mg/m 2. Patients who experience severe or cumulative cutaneous reactions or moderate neurosensory signs and/or symptoms during docetaxel therapy should have their dosage of docetaxel reduced from 75 mg/m 2 to 60 mg/m 2. If the patient continues to experience these reactions at 60 mg/m 2, treatment should be discontinued.
Non-small Cell Lung Cancer Monotherapy with docetaxel for NSCLC treatment after failure of prior platinum-based chemotherapy Patients who are dosed initially at 75 mg/m 2 and who experience either febrile neutropenia, neutrophils <500 cells/mm 3 for more than one week, severe or cumulative cutaneous reactions, or other grade 3/4 non-hematological toxicities during docetaxel treatment should have treatment withheld until resolution of the toxicity and then resumed at 55 mg/m 2. Patients who develop ≥grade 3 peripheral neuropathy should have docetaxel treatment discontinued entirely.
Combination therapy with docetaxel for chemotherapy-naive NSCLC For patients who are dosed initially at docetaxel 75 mg/m 2 in combination with cisplatin, and whose nadir of platelet count during the previous course of therapy is <25,000 cells/mm 3, in patients who experience febrile neutropenia, and in patients with serious non-hematologic toxicities, the docetaxel dosage in subsequent cycles should be reduced to 65 mg/m 2. In patients who require a further dose reduction, a dose of 50 mg/m 2 is recommended.
For cisplatin dosage adjustments, see manufacturers' prescribing information. Prostate Cancer Combination therapy with Docetaxel for metastatic castration-resistant prostate cancer Docetaxel should be administered when the neutrophil count is ≥1,500 cells/mm 3. Patients who experience either febrile neutropenia, neutrophils <500 cells/mm 3 for more than one week, severe or cumulative cutaneous reactions or moderate neurosensory signs and/or symptoms during docetaxel therapy should have the dosage of docetaxel reduced from 75 mg/m 2 to 60 mg/m 2.
If the patient continues to experience these reactions at 60 mg/m 2, the treatment should be discontinued. Gastric or Head and Neck Cancer Docetaxel in combination with cisplatin and fluorouracil in gastric cancer or head and neck cancer Patients treated with docetaxel in combination with cisplatin and fluorouracil must receive antiemetics and appropriate hydration according to current institutional guidelines.
In both studies, G-CSF was recommended during the second and/or subsequent cycles in case of febrile neutropenia, or documented infection with neutropenia, or neutropenia lasting more than 7 days. If an episode of febrile neutropenia, prolonged neutropenia or neutropenic infection occurs despite G-CSF use, the docetaxel dose should be reduced from 75 mg/m 2 to 60 mg/m 2.
If subsequent episodes of complicated neutropenia occur the docetaxel dose should be reduced from 60 mg/m 2 to 45 mg/m 2. In case of grade 4 thrombocytopenia the docetaxel dose should be reduced from 75 mg/m 2 to 60 mg/m 2. Do not retreat patients with subsequent cycles of docetaxel until neutrophils recover to a level >1,500 cells/mm 3 [see Contraindications (4)].
Avoid retreating patients until platelets recover to a level >100,000 cells/mm 3. Discontinue treatment if these toxicities persist [see Warnings and Precautions (5.3)]. Recommended dose modifications for toxicities in patients treated with docetaxel in combination with cisplatin and fluorouracil are shown in Table 1. Table 1: Recommended Dose Modifications for Toxicities in Patients Treated with Docetaxel in Combination with Cisplatin and Fluorouracil Toxicity Dosage adjustment Diarrhea grade 3 First episode: reduce fluorouracil dose by 20%.
Second episode: then reduce docetaxel dose by 20%. Diarrhea grade 4 First episode: reduce docetaxel and fluorouracil doses by 20%. Second episode: discontinue treatment. Stomatitis/mucositis grade 3 First episode: reduce fluorouracil dose by 20%. Second episode: stop fluorouracil only, at all subsequent cycles. Third episode: reduce docetaxel dose by 20%.
Stomatitis/mucositis grade 4 First episode: stop fluorouracil only, at all subsequent cycles. Second episode: reduce docetaxel dose by 20%. Liver dysfunction: In case of AST/ALT >2.5 to ≤5 × ULN and AP ≤2.5 × ULN, or AST/ALT >1.5 to ≤5 × ULN and AP >2.5 to ≤5 × ULN, docetaxel should be reduced by 20%. In case of AST/ALT >5 × ULN and/or AP >5 × ULN docetaxel should be stopped.
The dose modifications for cisplatin and fluorouracil in the gastric cancer study are provided below. Cisplatin dose modifications and delays Peripheral neuropathy: A neurological examination should be performed before entry into the study, and then at least every 2 cycles and at the end of treatment. In the case of neurological signs or symptoms, more frequent examinations should be performed and the following dose modifications can be made according to NCI-CTCAE grade: Grade 2: Reduce cisplatin dose by 20%.
Grade 3: Discontinue treatment. Ototoxicity: In the case of grade 3 toxicity, discontinue treatment. Nephrotoxicity: In the event of a rise in serum creatinine ≥grade 2 (>1.5 × normal value) despite adequate rehydration, CrCl should be determined before each subsequent cycle and the following dose reductions should be considered (see Table 2).
For other cisplatin dosage adjustments, also refer to the manufacturers' prescribing information. Table 2: Dose Reductions for Evaluation of Creatinine Clearance Creatinine clearance result before next cycle Cisplatin dose next cycle CrCl = Creatinine clearance CrCl ≥60 mL/min Full dose of cisplatin was given. CrCl was to be repeated before each treatment cycle.
CrCl between 40 and 59 mL/min Dose of cisplatin was reduced by 50% at subsequent cycle. If CrCl was >60 mL/min at end of cycle, full cisplatin dose was reinstituted at the next cycle. If no recovery was observed, then cisplatin was omitted from the next treatment cycle. CrCl <40 mL/min Dose of cisplatin was omitted in that treatment cycle only.
If CrCl was still <40 mL/min at the end of cycle, cisplatin was discontinued. If CrCl was >40 and <60 mL/min at end of cycle, a 50% cisplatin dose was given at the next cycle. If CrCl was >60 mL/min at end of cycle, full cisplatin dose was given at next cycle. Fluorouracil dose modifications and treatment delays For diarrhea and stomatitis, see Table 1.
In the event of grade 2 or greater plantar-palmar toxicity, fluorouracil should be stopped until recovery. The fluorouracil dosage should be reduced by 20%. For other greater than grade 3 toxicities, except alopecia and anemia, chemotherapy should be delayed (for a maximum of 2 weeks from the planned date of infusion) until resolution to grade ≤1 and then recommenced, if medically appropriate.
For other fluorouracil dosage adjustments, also refer to the manufacturers' prescribing information. Combination Therapy with Strong CYP3A4 Inhibitors Avoid using concomitant strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole).
There are no clinical data with a dose adjustment in patients receiving strong CYP3A4 inhibitors. Based on extrapolation from a pharmacokinetic study with ketoconazole in 7 patients, consider a 50% docetaxel dose reduction if patients require coadministration of a strong CYP3A4 inhibitor [see Drug Interactions (7), Clinical Pharmacology (12.3)].
2.8 Administration Precautions
2.8 Administration Precautions Docetaxel is a hazardous anticancer drug and, as with other potentially toxic compounds, caution should be exercised when handling and preparing docetaxel solutions. The use of gloves is recommended [see How Supplied/Storage and Handling (16.3)]. If Docetaxel injection initial diluted solution, or final dilution for infusion should come into contact with the skin, immediately and thoroughly wash with soap and water.
If Docetaxel injection initial diluted solution, or final dilution for infusion should come into contact with mucosa, immediately and thoroughly wash with water. Contact of the docetaxel with plasticized PVC equipment or devices used to prepare solutions for infusion is not recommended. In order to minimize patient exposure to the plasticizer DEHP (di-2-ethylhexyl phthalate), which may be leached from PVC infusion bags or sets, the final docetaxel dilution for infusion should be stored in bottles (glass, polypropylene) or plastic bags (polypropylene, polyolefin) and administered through polyethylene-lined administration sets.
One-vial Docetaxel (Injection) Docetaxel injection requires NO prior dilution with a diluent and is ready to add to the infusion solution. Please follow the preparation instructions provided below.
2.9 Preparation and Administration DO
2.9 Preparation and Administration DO NOT use the two-vial formulation (Injection and diluent) with the one-vial formulation. One-vial Docetaxel (Injection) Docetaxel injection (20 mg/mL) requires NO prior dilution with a diluent and is ready to add to the infusion solution. Use only a 21-gauge needle to withdraw docetaxel from the vial because larger bore needles (e.g., 18 and 19 gauge) may result in stopper coring and rubber particulates.
Docetaxel vials should be stored between 2°C and 25°C (36°F and 77°F). If the vials are stored under refrigeration, allow the appropriate number of vials of Docetaxel injection vials to stand at room temperature for approximately 5 minutes before use. Using only a 21-gauge needle, aseptically withdraw the required amount of Docetaxel injection (20 mg docetaxel/mL) with a calibrated syringe and inject via a single injection (one shot) into a 250 mL infusion bag or bottle of either 0.9% Sodium Chloride solution or 5% Dextrose solution to produce a final concentration of 0.3 mg/mL to 0.74 mg/mL.
If a dose greater than 200 mg of docetaxel is required, use a larger volume of the infusion vehicle so that a concentration of 0.74 mg/mL docetaxel is not exceeded. Thoroughly mix the infusion by gentle manual rotation. As with all parenteral products, docetaxel should be inspected visually for particulate matter or discoloration prior to administration whenever the solution and container permit.
If the docetaxel dilution for intravenous infusion is not clear or appears to have precipitation, it should be discarded. Docetaxel infusion solution is supersaturated, therefore may crystallize over time. If crystals appear, the solution must no longer be used and shall be discarded. The docetaxel dilution for infusion should be administered intravenously as a 1-hour infusion under ambient room temperature (below 25°C) and lighting conditions.
2.10 Stability
2.10 Stability Docetaxel final dilution for infusion, if stored between 2°C and 25°C (36°F and 77°F) is stable for 6 hours. Docetaxel final dilution for infusion (in either 0.9% Sodium Chloride solution or 5% Dextrose solution) should be used within 6 hours (including the 1 hour intravenous administration). In addition, physical and chemical in-use stability of the infusion solution prepared as recommended has been demonstrated in non-PVC bags up to 48 hours when stored between 2°C and 8°C (36°F and 46°F).
Dosing: Altered kidney function
Nephrotoxicity: In the event of a rise in serum creatinine ≥grade 2 (>1.5 × normal value) despite adequate rehydration, CrCl should be determined before each subsequent cycle and the following dose reductions should be considered (see Table 2 ).
Table 2: Dose Reductions for Evaluation of Creatinine Clearance Creatinine clearance result before next cycle Cisplatin dose next cycle CrCl = Creatinine clearance CrCl ≥60 mL/min Full dose of cisplatin was given.
CrCl was to be repeated before each treatment cycle.
CrCl between 40 and 59 mL/min Dose of cisplatin was reduced by 50% at subsequent cycle.
If CrCl was >60 mL/min at end of cycle, full cisplatin dose was reinstituted at the next cycle.
CrCl <40 mL/min Dose of cisplatin was omitted in that treatment cycle only.
If CrCl was still <40 mL/min at the end of cycle, cisplatin was discontinued.
If CrCl was >40 and <60 mL/min at end of cycle, a 50% cisplatin dose was given at the next cycle.
If CrCl was >60 mL/min at end of cycle, full cisplatin dose was given at next cycle.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment Avoid docetaxel in patients with bilirubin >ULN and patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN [see Boxed Warning, Warnings and Precautions (5.2), Clinical Pharmacology (12.3)]. The alcohol content of Docetaxel injection should be taken into account when given to patients with hepatic impairment [see Warnings and Precautions (5.13)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The alcohol content of Docetaxel injection should be taken into account when given to pediatric patients [see Warnings and Precautions (5.13)]. The efficacy of docetaxel in pediatric patients as monotherapy or in combination has not been established. The overall safety profile of docetaxel in pediatric patients receiving monotherapy or TCF was consistent with the known safety profile in adults.
Docetaxel has been studied in a total of 289 pediatric patients: 239 in 2 trials with monotherapy and 50 in combination treatment with cisplatin and 5-fluorouracil (TCF). Docetaxel Monotherapy Docetaxel monotherapy was evaluated in a dose-finding phase 1 trial in 61 pediatric patients (median age 12.5 years, range 1–22 years) with a variety of refractory solid tumors.
The recommended dose was 125 mg/m 2 as a 1-hour intravenous infusion every 21 days. The primary dose limiting toxicity was neutropenia. The recommended dose for docetaxel monotherapy was evaluated in a phase 2 single-arm trial in 178 pediatric patients (median age 12 years, range 1–26 years) with a variety of recurrent/refractory solid tumors.
Efficacy was not established with tumor response rates ranging from one complete response (CR) (0.6%) in a patient with undifferentiated sarcoma to four partial responses (2.2%) seen in one patient each with Ewing Sarcoma, neuroblastoma, osteosarcoma, and squamous cell carcinoma. Docetaxel in Combination Docetaxel was studied in combination with cisplatin and 5-fluorouracil (TCF) versus cisplatin and 5-fluorouracil (CF) for the induction treatment of nasopharyngeal carcinoma (NPC) in pediatric patients prior to chemoradiation consolidation.
Seventy-five patients (median age 16 years, range 9 to 21 years) were randomized (2:1) to docetaxel (75 mg/m 2) in combination with cisplatin (75 mg/m 2) and 5-fluorouracil (750 mg/m 2) (TCF) or to cisplatin (80 mg/m 2) and 5-fluorouracil (1000 mg/m 2 /day) (CF). The primary endpoint was the CR rate following induction treatment of NPC.
One patient out of 50 in the TCF group (2%) had a complete response while none of the 25 patients in the CF group had a complete response. Pharmacokinetics Pharmacokinetic parameters for docetaxel were determined in 2 pediatric solid tumor trials. Following docetaxel administration at 55 mg/m 2 to 235 mg/m 2 in a 1-hour intravenous infusion every 3 weeks in 25 patients aged 1 to 20 years (median 11 years), docetaxel clearance was 17.3±10.9 L/h/m 2.
Docetaxel was administered in combination with cisplatin and 5-fluorouracil (TCF), at dose levels of 75 mg/m 2 in a 1-hour intravenous infusion day 1 in 28 patients aged 10 to 21 years (median 16 years, 17 patients were older than 16). Docetaxel clearance was 17.9±8.75 L/h/m 2, corresponding to an AUC of 4.20±2.57 μg∙h/mL.
In summary, the body surface area adjusted clearance of docetaxel monotherapy and TCF combination in children were comparable to those in adults [see Clinical Pharmacology (12.3)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy in elderly patients. Non-small Cell Lung Cancer In a study conducted in chemotherapy-naive patients with NSCLC (TAX326), 148 patients (36%) in the docetaxel+cisplatin group were 65 years of age or greater.
There were 128 patients (32%) in the vinorelbine+cisplatin group 65 years of age or greater. In the docetaxel+cisplatin group, patients less than 65 years of age had a median survival of 10.3 months (95% CI: 9.1 months, 11.8 months) and patients 65 years or older had a median survival of 12.1 months (95% CI: 9.3 months, 14 months).
In patients 65 years of age or greater treated with docetaxel+cisplatin, diarrhea (55%), peripheral edema (39%) and stomatitis (28%) were observed more frequently than in the vinorelbine+cisplatin group (diarrhea 24%, peripheral edema 20%, stomatitis 20%). Patients treated with docetaxel+cisplatin who were 65 years of age or greater were more likely to experience diarrhea (55%), infections (42%), peripheral edema (39%) and stomatitis (28%) compared to patients less than the age of 65 administered the same treatment (43%, 31%, 31% and 21%, respectively).
When docetaxel was combined with carboplatin for the treatment of chemotherapy-naive, advanced non-small cell lung carcinoma, patients 65 years of age or greater (28%) experienced higher frequency of infection compared to similar patients treated with docetaxel+cisplatin, and a higher frequency of diarrhea, infection and peripheral edema than elderly patients treated with vinorelbine+cisplatin. Prostate Cancer Of the 333 patients treated with docetaxel every three weeks plus prednisone in the prostate cancer study (TAX327), 209 patients were 65 years of age or greater and 68 patients were older than 75 years.
In patients treated with docetaxel every three weeks, the following treatment-emergent adverse reactions occurred at rates ≥10% higher in patients 65 years of age or greater compared to younger patients: anemia (71% vs 59%), infection (37% vs 24%), nail changes (34% vs 23%), anorexia (21% vs 10%), weight loss (15% vs 5%), respectively. Breast Cancer In the adjuvant breast cancer trial (TAX316), docetaxel in combination with doxorubicin and cyclophosphamide was administered to 744 patients of whom 48 (6%) were 65 years of age or greater.
The number of elderly patients who received this regimen was not sufficient to determine whether there were differences in safety and efficacy between elderly and younger patients. Gastric Cancer Among the 221 patients treated with docetaxel in combination with cisplatin and fluorouracil in the gastric cancer study, 54 were 65 years of age or older and 2 patients were older than 75 years.
In this study, the number of patients who were 65 years of age or older was insufficient to determine whether they respond differently from younger patients. However, the incidence of serious adverse reactions was higher in the elderly patients compared to younger patients. The incidence of the following adverse reactions (all grades, regardless of relationship): lethargy, stomatitis, diarrhea, dizziness, edema, febrile neutropenia/neutropenic infection occurred at rates ≥10% higher in patients who were 65 years of age or older compared to younger patients.
Elderly patients treated with TCF should be closely monitored. Head and Neck Cancer Among the 174 and 251 patients who received the induction treatment with docetaxel in combination with cisplatin and fluorouracil (TPF) for SCCHN in the TAX323 and TAX324 studies, 18 (10%) and 32 (13%) of the patients were 65 years of age or older, respectively.
These clinical studies of docetaxel in combination with cisplatin and fluorouracil in patients with SCCHN did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience with this treatment regimen has not identified differences in responses between elderly and younger patients.
Administration
2.8 Administration Precautions Docetaxel is a hazardous anticancer drug and, as with other potentially toxic compounds, caution should be exercised when handling and preparing docetaxel solutions. The use of gloves is recommended [see How Supplied/Storage and Handling (16.3) ] . If Docetaxel injection initial diluted solution, or final dilution for infusion should come into contact with the skin, immediately and thoroughly wash with soap and water. If Docetaxel injection initial diluted solution, or final dilution for infusion should come into contact with mucosa, immediately and thoroughly wash with water. Contact of the docetaxel with plasticized PVC equipment or devices used to prepare solutions for infusion is not recommended. In order to minimize patient exposure to the plasticizer DEHP (di-2-ethylhexyl phthalate), which may be leached from PVC infusion bags or sets, the final docetaxel dilution for infusion should be stored in bottles (glass, polypropylene) or plastic bags (polypropylene, polyolefin) and administered through polyethylene-lined administration sets. One-vial Docetaxel (Injection) Docetaxel injection requires NO prior dilution with a diluent and is ready to add to the infusion solution. Please follow the preparation instructions provided below.
2.9 Preparation and Administration DO NOT use the two-vial formulation (Injection and diluent) with the one-vial formulation. One-vial Docetaxel (Injection) Docetaxel injection (20 mg/mL) requires NO prior dilution with a diluent and is ready to add to the infusion solution. Use only a 21-gauge needle to withdraw docetaxel from the vial because larger bore needles (e.g., 18 and 19 gauge) may result in stopper coring and rubber particulates. Docetaxel vials should be stored between 2°C and 25°C (36°F and 77°F). If the vials are stored under refrigeration, allow the appropriate number of vials of Docetaxel injection vials to stand at room temperature for approximately 5 minutes before use. Using only a 21-gauge needle, aseptically withdraw the required amount of Docetaxel injection (20 mg docetaxel/mL) with a calibrated syringe and inject via a single injection (one shot) into a 250 mL infusion bag or bottle of either 0.9% Sodium Chloride solution or 5% Dextrose solution to produce a final concentration of 0.3 mg/mL to 0.74 mg/mL. If a dose greater than 200 mg of docetaxel is required, use a larger volume of the infusion vehicle so that a concentration of 0.74 mg/mL docetaxel is not exceeded. Thoroughly mix the infusion by gentle manual rotation. As with all parenteral products, docetaxel should be inspected visually for particulate matter or discoloration prior to administration whenever the solution and container permit. If the docetaxel dilution for intravenous infusion is not clear or appears to have precipitation, it should be discarded. Docetaxel infusion solution is supersaturated, therefore may crystallize over time. If crystals appear, the solution must no longer be used and shall be discarded. The docetaxel dilution for infusion should be administered intravenously as a 1-hour infusion under ambient room temperature (below 25°C) and lighting conditions.
2.10 Stability Docetaxel final dilution for infusion, if stored between 2°C and 25°C (36°F and 77°F) is stable for 6 hours. Docetaxel final dilution for infusion (in either 0.9% Sodium Chloride solution or 5% Dextrose solution) should be used within 6 hours (including the 1 hour intravenous administration). In addition, physical and chemical in-use stability of the infusion solution prepared as recommended has been demonstrated in non-PVC bags up to 48 hours when stored between 2°C and 8°C (36°F and 46°F).
US FDA labelDosage forms
Philippines
- Concentrate solution for iv infusion: 10 mg/mL, 20 mg/0.5 mL, 20 mg/mL, 20 mg/mL, 80 mg/4 mL and 120 mg/6 mL, 40 mg/mL, 80 mg/2 mL, 80 mg/4 mL, 120 mg/3 mL
- ) concentrate solution for iv infusion: 20 mg/0.5 mL (80 mg/2 mL, 40 mg/mL (20 mg/0.5 mL, 40 mg/mL (80 mg/2 mL
- Concentrate solution for i.v. infusion: 20 mg/0.5 mL, 20 mg/mL, 80 mg/2 mL, 120 mg/3 mL
- Concentrate for solution for iv infusion: 20 mg/0.5 mL, 20 mg/mL, 40 mg/mL, 80 mg/2 mL, 80 mg/4 mL, 120 mg/3 mL
- ) solution for intravenous infusion: 10 mg/mL (120 mg/12 mL, 10 mg/mL (20 mg/2 mL, 10 mg/mL (80 mg/8 mL, 10 mg/mL (80 mg/mL
- ) concentrate solution for infusion: 20 mg/mL (100 mg/5 mL, 20 mg/mL (80 mg/4 mL
- ) concentrated solution for iv infusion: 40 mg/mL (20 mg/0.5 mL, 40 mg/mL (80 mg/2 mL
- ) solution for iv infusion: 20 mg/2 mL (10 mg/mL, 20 mg/mL (80 mg/4 mL, 80 mg/8 mL (10 mg/mL
- Concentrate for solution for infusion: 10 mg/mL, 20 mg/mL, 80 mg/2 mL
- ) concentrate for solution for i.v. infusion: 10 mg/mL (20 mg/2 mL and 80 mg/8 mL, 20 mg/mL (80 mg/4 mL
and 28 more forms; see the products table.
Registered products in the Philippines
126 products registered with the Food and Drug Administration (FDA) Philippines list Docetaxel as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Docetaxel With Solvent (1 product). Products registered under these spellings are included in the table and marked.
All registered products126
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Admoxel- 20Docetaxel (as Trihydrate) | 20mg/0.5mL Concentrate Solution for IV Infusion5 mL-capacity USP Type I glass vial with grey bromobutyl rubber stopper and grey aluminum flip-off seal x 0.5 mL + 5 mL-capacity USP Type I glass vial with bromobutyl rubber stopper and grey aluminum flip-off seal x 1.5 mL containing Water for Injection (as diluent) [Box of 1's] | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DR-XY47919 | Apr 8, 2027 | |
Admoxel- 80Docetaxel (as Trihydrate) | 80mg/2mL Concentrate Solution for IV Infusion10 mL-capacity USP Type I glass vial with grey bromobutyl rubber stopper and yellow aluminum flip-off seal x 2 mL + 10 mL-capacity USP Type I glass vial with bromobutyl rubber stopper and yellow aluminum flip-off seal x 6 mL containing Water for Injection (as diluent) [Box of 1's] | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DR-XY47920 | Apr 8, 2027 | |
Admoxel-120Docetaxel (as trihydrate) | 120 mg / 3 mL Concentrate for Solution for IV Infusion20 mL -capacity USP Type I glass vial with grey bromobutyl rubber stopper and purple aluminum flip-off seal x 3 mL + 20 mL-capacity USP Type I glass vial with bromobutyl rubber stopper and purple aluminum flip-off seal x 9 mL containing Water for Injection (as diluent) [Box of 1's] | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DRP-14476 | Apr 8, 2027 | |
Admoxel-120Docetaxel (as Trihydrate) | 120mg/3mL Concentrate Solution for IV InfusionUSP Type I glass vial with grey bromobutyl rubber stopper and purple aluminum flip-off seal x 3 mL + 20 mL-capacity USP Type I glass vial with bromobutyl rubber stopper and purple aluminum flip-off seal x 9 mL containing Water for Injection (as diluent) [Box of 1's] | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DR-XY47918 | Apr 8, 2027 | |
Admoxel-20Docetaxel (as trihydrate) | 20 mg / 0.5 mL Concentrate for Solution for IV Infusion5 mL-capacity USP Type I glass vial with grey bromobutyl rubber stopper and grey aluminum flip-off seal x 0.5 mL + 5 mL-capacity USP Type I glass vial with bromobutyl rubber stopper and grey aluminum flip-off seal x 1.5 mL containing Water for Injection (as diluent) [Box of 1's] | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DRP-14477 | Apr 8, 2027 | |
Admoxel-80Docetaxel (as trihydrate) | 80 mg / 2 mL Concentrate for Solution for IV Infusion10 mL- capacity USP Type I glass vial with grey bromobutyl rubber stopper and yellow aluminum flip-off seal x 2 mL + 10 mL- capacity USP Type I glass vial with bromobutyl rubber stopper and yellow aluminum flip-off seal x 6 mL containing Water for Injection (as diluent) [Box of 1's] | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DRP-14479 | Apr 8, 2027 | |
AmnoticDocetaxel (as trihydrate) | 20 mg/0.5 mL Concentrate Solution for IV Infusion0.5 mL in 5 mL USP Type I Clear Glass Vial with bromobutyl rubber stopper and blue aluminum flip-off seal + 1.5 mL in 5 mL USP Type I Clear Glass Vial with white colour aluminum flip-off seal (diluent) (Box of 1's) | RxVAT-exempt | Adley FormulationsIndia | ASA LIFE PHILIPPINES LIMITED INC | DRP-5351 | Aug 26, 2029 | |
AnmoticDocetaxel (as trihydrate) | 40 mg/mL Concentrate Solution for IV Infusion2 mL in 10 mL-capacity USP Type I vial with bromobutyl rubber stopper and blue colored aluminum flip-off seal+ 6 mL in 10 mL-capacity USP Type I with bromo butyl rubber stopper and white colored aluminum flip-off seal ethanol (diluent) (Box of 2 vials in plastic tray) | RxVAT-exempt | Adley Formulations Pvt. Ltd.India | Asa Life Philippines Limited Inc | DR-XY44097 | Feb 20, 2031 | |
BagotaxDocetaxel | 20 mg/0.5 mL Concentrate Solution for Intravenous InfusionUSP Type I transparent glass vial in 0.5 mL (net content as active) + USP Type I transparent glass vial in 1.83 mL (net content as diluent) (Box of 1's) | RxVAT-exempt | Bioprofarma Bago S.A.Argentine Republic | Apolloplus Capital Inc. | DR-XY44248 | Feb 27, 2030 | |
BagotaxDocetaxel | 40 mg/mL (80 mg/2 mL) Concentrate Solution for Intravenous InfusionUSP Type I transparent glass vial in 2 mL (net content as active) + USP Type I transparent glass vial in 7.32 mL (net content as diluent) (Box of 1's) | RxVAT-exempt | Bioprofarma Bago S.A.Argentine Republic | Apolloplus Capital Inc. | DR-XY44249 | Feb 27, 2030 | |
BelcytereDocetaxel | 20 mg/mL (80 mg/4mL) (160 mg/8 mL) Solution for Injection (IV Infusion)5 mL Type I Clear Glass Vial Sealed with Gray Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1mL and 4 mL (Net content) 15 mL Type I Clear Glass Vial Sealed with Gray Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 8 mL (Net content) | RxVAT-exempt | Biolyse Pharma CorporationCanada | Importer: Belcynor Pharmaceuticals, Inc. | DR-XY48246 | Jul 29, 2027 | |
Brexel 20Docetaxel | 20 mg/2 mL Solution for IV InjectionClear Type I Glass Vial with Gray Bromobutyl Rubber Stopper x 2 mL (Box of 1's) | RxVAT-exempt | PT. Global Onkolab FarmaIndonesia | Globo Asiatico Enterprises, Inc. | DR-XY48640 | Mar 7, 2031 | |
Brexel 80Docetaxel | 10 mg/mL (80 mg/ 8 mL) Solution for Injection for I.V. InfusionUSP Type I clear glass vial with Grey Bromobutyl rubber stopper and Aluminum cap with plastic seal flip off x 8. mL (Box of 1's). | RxVAT-exempt | PT. Global Onkolab FarmaIndonesia | Globo Asiatico Enterprises, Inc.Trader: Kalbe International Pte, Ltd. | DR-XY48646 | Mar 9, 2028 | |
CeltereDocetaxel | 20 mg/0.5 mL Concentrate for Injection (IV)USP Type I Clear Glass vial x 0.5 mL with diluent (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E. Medica, Inc. | DRP-1486 | Dec 3, 2031 | |
CeltereDocetaxel (as trihydrate) | 40 mg/mL Concentrate Solution for IV InfusionIn a box containing 20 mL-capacity USP type I glass vial with grey colored bromobutyl rubber stopper and red colored aluminum flip-off seal + USP type I glass vial with bromobutyl stopper and red colored aluminum flip-off seal x 6 mL as diluent Box of 1 vial x 2 mL + 1 vial diluent; In a box containing 20 mL-capacity USP type I glass vial with grey colored bromobutyl rubber stopper and red colored aluminum flip-off seal + USP type I glass vial with bromobutyl stopper and red colored aluminum flip-off seal x 6 mL as diluent Box of l vial x 3 mL + l vial diluent | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E. Medica, Inc | DRP-1320 | Mar 11, 2029 | |
Chetax-20Docetaxel (as trihydrate) | 20 mg/0.5 mL Concentrate Solution for Injection I.V. InfusionUSP Type I clear colourless glass vial with bromo with butyl rubber stopper and grey flip off seal x 0.5 mL + USP Type I clear colourless glass vial with bromo butyl rubber stopper and green flip off seal x 1.5 mL containing Absolute alcohol (as diluent) in a box. | RxVAT-exempt | ADMAC Lifesciences.India | Orange Biotec Inc. | DRP-13303 | Jan 20, 2028 | |
Chetax-80Docetaxel (as trihydrate) | 40 mg/mL (80 mg/2 mL) Concentrate Solution for IV InfusionUSP Type I clear moulded glass vial with grey. bromobutyl rubber stopper and yellow flip off seal x 2 mL USP Type I clear moulded glass vial with grey bromobutyl rubber stopper and white flip off seal x 6 mL containing Absolute alcohol (as diluent) in a box | RxVAT-exempt | Admac LifesciencesIndia | Orange Biotec Inc. | DRP-13522 | Mar 3, 2028 | |
D-TailDocetaxel (as Trihydrate) | 20 mg/ 0.5 mL Concentrated Solution for Injection (IV Infusion)0.5 mL in 5 mL Amber Glass Vial USP Type I+ 1.5 mL Absolute Alcohol (as solvent) in 5 mL Flint Glass Vial Type I Box of 1 's | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Medethix, Inc. | DRP-5700 | Nov 10, 2029 | |
DaxotelDocetaxel | 20 mg/mL Concentrate Solution for I. V. Infusion1 mL, 4 mL, and 6 mL USP Type I Clear Glass Vial (Box of 1's) | RxVAT-exempt | Fresenius Kabi Oncology LimitedIndia | Fresenius Kabi Philippines, Inc.Trader: Fresenius Kabi Asia Pacific Ltd. | DR-XY45717 | Feb 3, 2030 | |
DocebilDocetaxel | 80 mg/ 2 mL Concentrate for Solution for (IV) InfusionBox of 2 vials containing:10 mL-capacity USP Type I glass vial with grey bromobutyl serum rubber stopper and sealed with green colored flip-off seal x 2 mL + 10 mL capacity USP Type I glass vial with grey colored bromobutyl serum rubber stopper and sealed with brown colored flip-off seal x 7 mL (diluent) | RxVAT-exempt | SP Accure Labs Pvt. Ltd.India | Hexagon PharmaceuticalsTrader: Abil Chempharma Pvt. Ltd. | DR-XY48274 | Aug 12, 2027 | |
Docegard 20Docetaxel | 40 mg/mL (20 mg/0.5 mL) Concentrate Solution for IV Infusion5 mL-capacity USP Type I Clear Glass Vial sealed with 20 mm Omniflex Rubber Stopper and non-tear-off Aluminum Seal with Red Polypropylene Flip-Off Cap x 0.5 mL (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8581-04 | Dec 18, 2029 | |
Docegard 80Docetaxel | 40 mg / mL (80 mg / 2 mL) Concentrate Solution for IV Infusion15 mL -capacity USP Type I clear glass vial sealed with 20 mm omniflex rubber stopper and non-tear-off aluminum seal with red polypropylene flip-off cap x 2 mL (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8580-04 | Dec 18, 2029 | |
Docegen-20Docetaxel | 40 mg/mL (20 mg/0.5 mL) Concentrate Solution for IV Infusion5 mL-Capacity USP Type I clear glass vial sealed with 20 mm Omniflex Rubber stopper and non-tear-off Aluminum Seal with Red Polypropylene Flip-Off Cap x 0.5 mL (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Amediqo Phils., Inc.Importer: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8581-01 | Dec 18, 2029 | |
Docegen-80Docetaxel | 40 mg/mL (80 mg/2 mL) Concentrate Solution for IV Infusion15 mL-capacity USP Type I clear glass vial sealed with 20 mm omniflex rubber stopper and non-tear off aluminum seal with red polypropylene flip-off cap x 2 mL (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Amediqo Phils., IncImporter: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8580-01 | Dec 18, 2029 | |
DocelexDocetaxel | 20 mg/0.5 mL Concentrate Solution for IV InfusionUSP Type I colorless vial with bromobutyl rubber stopper and white aluminum flip-off x 0.5 mL + USP Type I colorless vial with butyl rubber stopper and white aluminum flip-off seal x 1.5 mL water for injection (Box of 1's) | RxVAT-exempt | Laboratorio Kemex S.A.Argentine Republic | Delex Pharma International, Inc. | DRP-10615 | Oct 29, 2030 | |
DocelexDocetaxel | 40 mg/mL Concentrate Solution for IV InfusionUSP Type I colorless glass vial with bromobutyl rubber stopper and white aluminum flip-off seal x 2 mL + USP Type I colorless vial with butyl rubber stopper and white aluminum flip-off seal x 6 mL water for Injection (Box of 1's) | RxVAT-exempt | Laboratorio Kemex S.A.Argentine Republic | Delex Pharma International, Inc. | DRP-10616 | Oct 29, 2031 | |
DocemedDocetaxel | 40 mg/mL Concentrate for Solution for IV InfusionUSP Type I Clear Glass Vial with Bromo-Butyl Stopper and Red Colored Flip-off Seal + Water for Injection (diluent) Box of 1 containing 15 mL vial x 2 mL (active) + 1 vial x 6 mL (Diluent); Box of 1 containing 20 mL vial x 3 mL (active) + 1 vial x 9 mL (Diluent) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E. Medica, Inc. | DRP-6927 | Dec 19, 2031 | |
Docesanz-20Docetaxel (as trihydrate) | 20 mg/0.5 mL Concentrate Solution for I.V. Infusion5 mL capacity USP Type I clear glass vial x 0.5 mL + 5 mL capacity USP Type I clear glass vial x 1.5 mL as Solvent (Box of 1’s) | RxVAT-exempt | Admac LifesciencesIndia | Ambica International CorporationTrader: Unicare Healthsciences Private Limited | DRP-7747 | Nov 23, 2030 | |
Docesanz-80Docetaxel (as trihydrate) | 40 mg/mL (80 mg/2 mL) Concentrate Solution for IV Infusion10 mL Capacity USP Type I Clear Glass Vial x 2 mL + 10 mL Capacity USP Type I Clear Glass Vial x 6 mL as Solvent (Box of 1’s) | RxVAT-exempt | Admac LifesciencesIndia | Ambica International CorporationTrader: Unicare Healthsciences Private Limited | DRP-7749 | Nov 23, 2030 | |
DocetaxDocetaxel | 20 mg/ 0.5 mL Concentrate Solution for IV InfusionBox of 1 - Type I hydrolytic glass vial with grey bromobutyl elastomer rubber stopper and blue flip off metal cap x 0.5 mL + Type I hydrolytic glass vial x 1.5 mL water for injection (as diluent) | RxVAT-exempt | Laboratorios Richmond S.A.C.I.FRepublica Argentina | UNILAB, Inc. | DR-XY40210 | Oct 19, 2029 | |
DocetaxDocetaxel | 40 mg/mL (80 mg/2 mL) Concentrate Solution for IV InfusionBox of 1 - Type I hydrolytic glass vial with grey bromobutyl elastomer rubber stopper and violet flip-off metal cap x 2 mL + Type I hydrolytic glass vial x 6 mL water for injection (as diluent) | RxVAT-exempt | Laboratorios Richmond S.A.C.I.FRepublica Argentina | UNILAB, Inc. | DR-XY40211 | Oct 19, 2029 | |
DocetazeDocetaxel (as trihydrate) | 10 mg/mL (20 mg/2 mL and 80 mg/8 mL) Concentrate for Solution for I.V. Infusion | RxVAT-exempt | Shilpa Medicare Limited (Unit-IV PharmaceuticalIndia | Endure Medical, Inc. | DR-XY49642 | Feb 13, 2031 | |
DocetazeDocetaxel (as Trihydrate) | 20mg/mL (80 mg/ 4mL) Concentrated Solution for I.V. InfusionType I neck flint tubular glass vial with chlorobutyl rubber stopper and ligth blue aluminum flip off seal x 4 mL | RxVAT-exempt | Shilpa Medicare Limited, Unit-4 Formulations SezIndia | Endure Medical, Inc. | DR-XY49012 | Feb 28, 2029 | |
DocetazeDocetaxel (as Trihydrate) | 20mg/mL Concentrated Solution for I. V. InfusionType I neck flint tubular glass vial with chlorobutyl rubber stopper and ligth blue aluminum flip off seal x 1 mL | RxVAT-exempt | Shilpa Medicare Limited, Unit-4. Formulations SezIndia | Endure Medical, Inc. | DR-XY49011 | Feb 28, 2029 | |
DocetedDocetaxel (as trihydrate) | 20 mg/mL, 80 mg/4mL and 120 mg/6 mL Concentrate Solution for IV InfusionUSP Type I Clear Glass Vial in 1 mL, 4 mL and 6 mL (net content) Box of 1's | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | Medethix, Inc. | DRP-5795 | Nov 13, 2029 | |
Docetero 160Docetaxel | 20 mg (equivalent to 21.34 mg docetaxel trihydrate)/mL Concentrate Solution for IV InfusionType I clear glass ampoule with rubber stopper and aluminum flip-off seal x 15 mL (Box of 1's) | RxVAT-exempt | Hetero Labs Limited (Unit-VI)India | Camber Pharmaceuticals, Inc. | DRP-15645 | Aug 14, 2029 | |
Docetero 80Docetaxel (as trihydrate) | 20 mg/mL (80 mg/4 mL) Concentrate for Solution for I.V. Infusion5 mL capacity (4 mL net content) USP Type I clear and colorless glass vial with gray rubber stopper and aluminum seal with white plastic flip-off cap (box of 1 vial) | RxVAT-exempt | Hetero Labs Limited (Unit-VI)India | Camber Pharmaceuticals, Inc. | DRP-15898 | Sep 27, 2029 | |
DocewishDocetaxel (as Trihydrate) | 40 mg/mL (120 mg/3 mL) Concentrated Solution for I.V. InfusionClear USP Type I Glass Vial x 20 mL (Box of 1's); Clear USP Type I Glass Vial (13% Ethyl Alcohol) x 10 mL | RxVAT-exempt | Admac LifesciencesIndia | Ambica International Corporation | DRP-6846 | Oct 4, 2031 | |
DoctaxelDocetaxel (as trihydrate) | 120 mg/3 mL Concentrate Solution for I.V. InfusionUSP Type I flint glass vial in 3 mL (net content as active) + USP Type I flint glass vial in 9 mL (net content as diluent) (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Central West Medicale Inc.Importer: Ambica International Corporation | DRP-5971-01 | Jan 28, 2030 | |
DoctaxelDocetaxel (as trihydrate) | 20 mg/0.5 mL Concentrate Solution for I.V. InfusionOne (1) box contains: USP Type I flint glass vial in 0.5 mL (net content as active) + USP Type I flint glass vial in 1.5mL (net content as diluent) in a plastic tray. Box of 1’s | RxVAT-exempt | Getwell PharmaceuticalsIndia | Central West Medicale Inc.Importer: Ambica International Corporation | DRP-5972-02 | Jan 28, 2030 | |
DoctaxelDocetaxel (as trihydrate) | 80 mg/2 mL Concentrate Solution for I.V. InfusionOne (1) box contains: USP Type I flint glass vial in 2 mL (net content as active) + USP Type I flint glass vial in 6 mL (net content as diluent) in a plastic tray. (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Central West Medicale Inc.Importer: Ambica International Corporation | DRP-5973-01 | Jan 28, 2030 | |
DoseGet-120Docetaxel (as trihydrate) | 120 mg/3 mL Concentrate Solution for IV Infusion.20 mL USP Type I clear glass vial (3 mL net content finished product) with grey bromobutyl rubber stopper, aluminum seal and pink flip-off cap + USP Type I clear glass vial (9 mL net content diluent) in a plastic tray (Box of 1 finished product and 1 diluent) | RxVAT-exempt | Beta Drugs LimitedIndia | 2MG Incorporated | DRP-15309 | Jun 28, 2029 | |
Doseget-20Docetaxel (as trihydrate) | 20 mg/0.5mL Concentrate Solution for IV InfusionUSP Type I clear glass vial x 5 mL with rubber stopper and flip-off seal (Box of 1's) | RxVAT-exempt | Beta Drugs LimitedIndia | 2MG Incorporated | DRP-15784 | Sep 13, 2029 | |
DoseGet-20Docetaxel (as trihydrate) | 20 mg/mL Concentrate For Solution For IV InfusionUSP Type I clear glass vial with bromo butyl rubber plug and aluminum flip off seal x 5 mL (Box of 1's) | RxVAT-exempt | Beta Drugs LimitedIndia | 2MG Incorporated | DRP-17577 | Feb 3, 2031 | |
DoseGet-80Docetaxel (as trihydrate) | 20mg/mL (80 mg/4 mL) Concentrate For Solution For IV Infusion4 mL in 5 mL-capacity USP Type I clear glass vial with bromobutyl rubber stopper plug and aluminium flip off seal (Box of 1's) | RxVAT-exempt | Beta Drugs LimitedIndia | 2MG Incorporated | DRP-17576 | Feb 3, 2032 | |
Doseget-80Docetaxel (as trihydrate) | 40 mg/mL (80 mg/2 mL) Concentrate Solution for IV InfusionUSP Type I clear glass vial x 10 mL with rubber stopper and aluminum blue flip-off seal (Box of 1's) | RxVAT-exempt | Beta Drugs LimitedIndia | 2MG Incorporated | DRP-15786 | Sep 13, 2029 | |
Dotacel-20Docetaxel (as trihydrate) | 20 mg/0.5 mL Solution for Injection (IV)5 mL Capacity USP Type I clear and colorless glass Vial x 0.5 mL (net content) + Solvent x 1.5 mL (net Content) in USP Type I clear and colorless glass vial (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-6542 | Feb 24, 2038 | |
DotaxaDocetaxel | 40 mg/mL (80 mg/2 mL) Concentrate Solution for IVType I glass vial x 2 mL (net content) with bromobutyl rubber stopper, aluminum seal and blue flip-off cap (finished product) + USP Type I clear glass vial x 6 mL (net content) | RxVAT-exempt | Cisen Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-16118 | Nov 6, 2029 | |
Doxagen 20Docetaxel | 40 mg/mL (20 mg/0.5 mL) Concentrate Solution for IV Infusion5 mL-capacity USP Type I clear glass vial sealed with 20 mm Omniflex rubber stopper and non-tear off Aluminum seal with Red Polypropylene flip-off cap x 0.5 mL (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Kaufmann Pharma Inc.Importer: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8581-03 | Dec 18, 2029 | |
Doxagen 80Docetaxel | 40 mg/mL (80 mg/2 mL) Concentrate Solution for IV Infusion15 mL-capacity USP Type I clear glass vial sealed with 20 mm omniflex rubber stopper and non-tear off aluminum seal with red polypropylene flip-off cap x 2 mL (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Kaufmann Pharma Inc.Importer: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8580-03 | Dec 18, 2029 | |
DoxebestDocetaxel (as trihydrate) | 120 mg/3 mL Concentrated Solution for I.V. InfusionOne (1) box contains: USP Type I flint glass vial in 3 mL (net content as active) + USP Type I flint glass vial in 9 mL (net content as diluent) (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Detoxicare Philippines, Inc.Importer: Ambica International Corporation | DRP-5971-03 | Jan 28, 2030 | |
DoxebestDocetaxel (as trihydrate) | 20 mg/0.5 mL Concentrate Solution for I.V. InfusionOne (1) box contains: USP Type I flint glass vial in 0.5 mL (net content as active) + USP Type I flint glass vial in 1.5 mL (net content as diluent) in a plastic tray. (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Detoxicare Philippines, Inc.Importer: Ambica International Corporation | DRP-5972-04 | Jan 28, 2030 | |
DoxebestDocetaxel (as trihydrate) | 80 mg/2 mL Concentrate Solution for I.V. InfusionOne (1) box contains: USP Type I flint glass vial in 2 mL (net content as active) + USP Type I flint glass vial in 6 mL (net content as diluent) in a plastic tray. (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Detoxicare Philippines, Inc.Importer: Ambica International Corporation | DRP-5973-04 | Jan 28, 2030 | |
Doxebest-RTUDocetaxel | 20 mg/mL (80 mg/4 mL) Concentrate Solution for Infusion (I.V.)4 mL (Net Content) in a 15- mL Capacity USP Type I Flint Tubular Glass Vial with 20 mm Grey Rubber Stopper and Aluminum Seal with Yellow Flip-off Cap (Box of 1's) | RxVAT-exempt | Getwell Pharma India Pvt. Ltd.India | Detoxicare Phils., Inc.Importer: Ambica International Corporation | DRP-14331-01 | Aug 23, 2028 | |
Doxebest-RTUDocetaxel | 20 mg/mL Concentrate Solution for Infusion (I.V.)1 mL (Net Content) in a 5-mL Capacity USP Type I Flint Tubular Glass Vial with 20 mm Grey Rubber Stopper and Aluminum Seal with Yellow Flip-Off Cap (Box of 1's) | RxVAT-exempt | Getwell Pharma India Pvt. Ltd.India | Detoxicare Phils., Inc.Importer: Ambica International Corporation | DRP-14330-02 | Aug 23, 2028 | |
DoxelDocetaxel | 20 mg/mL Concentrate for Solution for IV Infusion2 mL-capacity USP Type I glass vial with grey chlorobutyl rubber stopper and green aluminum flip-off seal (Box of 1 vial x 1 mL); 6 mL-capacity USP Type I glass vial with grey chlorobutyl rubber stopper and orange aluminum flip-off seal (Box of 1 vial x.4 mL) | RxVAT-exempt | Sichuan Huiyu Pharmaceutical Company LimitedChina | Oncolife Corporation | DR-XY48248 | Aug 2, 2027 | |
DoxelDocetaxel | 20 mg/mL Concentrate Solution for IV InfusionUSP Type I clear colorless glass vial with 13mm grey chlorobutyl rubber stopper and green flip-off seal with aluminum shell and green plastic flip-off button x 1 mL (net content) (Box of 1's); USP Type I clear colorless glass vial with 20mm grey chlorobutyl rubber stopper and orange flip-off seal with aluminum shell and orange plastic flip-off button x 4 mL (net content) (Box of 1's) | RxVAT-exempt | Sichuan Huiyu Pharmaceutical Co., Ltd.China | Oncolife Corporation | DR-XY46691 | Sep 16, 2029 | |
DoxestadDocetaxel | 20mg/mL Concentrate for Solution for InfusionType I Colorless Glass Vial x 1 mL and 4 mL with Bromobutyl Rubber Stopper | RxVAT-exempt | Actavis Italy S.p.A.Italy | Detoxicare Philippines Inc.Importer: STADA Philippines Inc.Trader: STADPHARM GmbH | DR-XY43854 | Sep 13, 2027 | |
DoxetacentDocetaxel | 20 mg/ mL (100 mg/ 5 mL) Concentrate Solution for Infusion (I.V.)5 mL USP Type I Flint Tubular glass vial with 20 mm grey rubber stopper and aluminum seal with yellow flip- off cap (Box of 1's) | RxVAT-exempt | Getwell Pharma India Pvt. Ltd.India | Central West Medicale Inc.Importer: Ambica International Corporation | DRP-14330-01 | Aug 23, 2028 | |
DoxetacentDocetaxel (as trihydrate) | 20 mg/0.5 mL Concentrate Solution for I.V. InfusionOne (1) box contains: USP Type I flint glass vial in 0.5 mL (net content as active) + USP Type I flint glass vial in 1.5 mL (net content as diluent) in a plastic tray. (Box of 1’s) | RxVAT-exempt | Getwell Pharma India Pvt. Ltd.India | Central West Medicale Inc.Importer: Ambica International Corporation | DRP-5972-05 | Jan 28, 2030 | |
DoxetacentDocetaxel | 20 mg/mL (80 mg/4 mL) Concentrate Solution for Infusion (I.V.)4 mL (Net Content) in a 15-mL Capacity USP Type I Flint Tubular Glass Vial with 20 mm Grey Rubber Stopper and Aluminum Seal with Yellow Flip-off Cap (Box of 1's) | RxVAT-exempt | Getwell Pharma India Pvt. Ltd.India | Central West Medicale Inc.Importer: Ambica International Corporation | DRP-14331-02 | Aug 23, 2028 | |
DoxetacentDocetaxel (as trihydrate) | 80 mg/2 mL Concentrate Solution for I.V. InfusionOne (1) box contains: USP Type I flint glass vial in 2 mL (net content as active) + USP Type I flint glass vial in 6 mL (net content as diluent) in a plastic tray. (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Central West Medicale Inc.Importer: Ambica International Corporation | DRP-5973-05 | Jan 28, 2030 | |
DoxidDocetaxel | 20 mg/0.5 mL Solution for Intravenous InfusionUSP Type I Glass Vial + Diluent (Box of 1's) | RxVAT-exempt | Cisen Pharmaceutical Co. Ltd.China | Endure Medical, Inc. | DR-XY45402 | May 25, 2031 | |
DozantelDocetaxel | 10 mg/mL Concentrate for Solution for InfusionIn a box of 1 Ph. Eur. Type I Clear Glass Vial with a Bromobutyl Rubber Stopper and Aluminum Crimp Cap (2 mL and 8 mL); In a box of 5 Ph. Eur. Type I Clear Glass Vial with a Bromobutyl Rubber Stopper and Aluminum Crimp Cap (2 mL and 8 mL) | RxVAT-exempt | Fareva Unterach GmbHAustria | Sandoz Philippines Corporation | DRP-7593 | Jan 4, 2028 | |
EdocexilDocetaxel (as trihydrate) | 120 mg/3 mL Concentrate Solution for I.V. InfusionOne (1) box contains: USP Type I flint glass vial in 3 mL (net content as active) + USP Type I flint glass vial in 9 mL (net content as diluent) Box of 1’s | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprises, Inc.Importer: Ambica International Corporation | DRP-5971-02 | Jan 28, 2030 | |
EdocexilDocetaxel (as trihydrate) | 20 mg/0.5 mL Concentrate Solution for I.V. InfusionOne (1) box contains: USP Type I flint glass vial in 0.5 mL (net content as active) + USP Type I flint glass vial in 1.5mL (net content as diluent) in a plastic tray. Box of 1’s | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprises, Inc.Importer: Ambica International Corporation | DRP-5972-03 | Jan 28, 2030 | |
Emidocxal-20Docetaxel (as trihydrate) | 20 mg / 0.5 mL Concentrate for Solution for IV Infusion5 mL- capacity USP Type I glass vial with grey bromobutyl rubber stopper and grey aluminum flip-off seal x 0.5 mL + 5 mL -capacity USP Type I glass vial with bromobutyl rubber stopper and grey aluminum flip-off seal x 1.5 mL containing Water for Injection (as diluent) [Box of 1's] | RxVAT-exempt | Admac LifesciencesIndia | Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-14477-01 | Apr 8, 2027 | |
Emidocxal-80Docetaxel (as trihydrate) | 80 mg / 2 mL Concentrate for Solution for IV Infusion10 mL- capacity USP Type I glass vial with grey bromobutyl rubber stopper and yellow aluminum flip-off seal x 2 mL + 10 mL-capacity USP Type I glass vial with bromobutyl rubber stopper and yellow aluminum flip-off seal x 6 mL containing Water for Injection (as diluent) [Box of 1's] | RxVAT-exempt | Admac LifesciencesIndia | Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-14479-01 | Apr 8, 2027 | |
20 mg/0.5 mL (80 mg/2 mL) Concentrate Solution for IV Infusion20 mL-Capacity Type I Clear Glass Vial with Rubber Stopper and White Aluminum Flip-Off Seal x 2 mL+ Alcohol (as diluent) in 10 mL-Capacity Type I Clear Glass Vial with Rubber Stopper and White Aluminum Flip-Off Cap x 6 mL (Box of 1's) | Rx | VENUS REMEDIES , LIMITEDIndia | Importer: Finstad Inc. | DRP-14169 | Jul 12, 2028 | ||
FonkodecDocetaxel (as trihydrate) | 20 mg/mL Concentrate Solution for IV Infusion1 mL in 6 mL-capacity USP Type I Glass Vial with bromobutyl rubber stopper and green aluminium flip-off cap (Box of l's) | RxVAT-exempt | PT Fonko International PharmaceuticalsIndonesia | Glorious Dexa Mandaya, Inc.Trader: PT Ferron Par Pharmaceuticals | DRP-10903 | Dec 14, 2026 | |
FonkodecDocetaxel (as trihydrate) | 20mg/mL Concentrate Solution for IV Infusion4 mL in 6 mL-capacity USP Type I Glass Vial with bromobutyl rubber stopper and orange aluminium flip off cap (Box of 1's) | RxVAT-exempt | PT Fonko International PharmaceuticalsIndonesia | Glorious Dexa Mandaya, Inc.Trader: PT Ferron Par Pharmaceuticals | DRP-10902 | Dec 14, 2026 | |
GocetaxDocetaxel (as trihydrate) | 20 mg/0.5 mL Solution for Injection (IV)5 mL Capacity USP Type I clear and colorless glass Vial x 0.5 mL (net content) + Solvent x 1.5 mL (net content) in USP Type I clear and colorless glass vial (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Applied Pharmaceutical Distribution IncImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-6542-01 | Jul 24, 2037 | |
HentaxelDocetaxel | 40 mg/mL (80 mg/2 mL) Concentrate Solution for IV InfusionIndividually Boxed 2 mL Type I Glass Vial + 6 mL Diluent per box | RxVAT-exempt | Jiangsu Hengrui Medicine Co., Ltd.China | Goodfellow Pharma Corporation | DR-XY32287 | Mar 28, 2027 | |
HexcetDocetaxel | 80 mg/2 mL Concentrate for Solution for IV InfusionBox of 2 vials containing:10 mL-capacity USP Type I glass vial with grey bromobutyl serum rubber stopper and sealed with green colored flip-off seal x 2 mL + 10 mL capacity USP Type I glass vial with grey colored bromobutyl serum rubber stopper and sealed with brown colored flip-off seal x 7 mL (diluent) | RxVAT-exempt | SP Accure Labs Pvt. Ltd.India | Hexagon PharmaceuticalsTrader: Abil Chempharma Pvt. Ltd. | DR-XY48275 | Aug 11, 2027 | |
KintaxDocetaxel | 20 mg/ 2 mL (10 mg/mL) Solution for IV InfusionType I Clear Vial with Laminated Chlorobutyl Rubber Stopper and Red flip-off Seal x 2 mL (Box of 1's) | RxVAT-exempt | Kindos Pharmaceutical Co., Ltd.China | Goodfellow Pharma Corporation | DR-XY49198 | Sep 10, 2029 | |
KintaxDocetaxel | 80 mg/ 8 mL (10 mg/mL) Solution for IV InfusionType I Clear Vial with Laminated Chlorobutyl Rubber Stopper and Red flip-off Seal x 10 mL (Box of 1's) | RxVAT-exempt | Kindos Pharmaceutical Co., Ltd.China | Goodfellow Pharma Corporation | DR-XY49197 | Sep 10, 2029 | |
Maxtaxel-20Docetaxel (as trihydrate) | 20 mg/0.5 mL Concentrate Solution for Injection. (IV Infusion)5 mL-Type 1 Clear Borosilicate Tubular Glass Vial Sealed with Gray Butyl Rubber Stopper and Aluminum Flip-Off Seal Cap + 1.5 mL (net content) Diluents in 5 mL-Type 1 Clear Borosilicate Tubular Glass Vial Sealed with Gray Butyl Rubber Stopper and Aluminum Flip-Off Seal Cap (Box of 1's) | RxVAT-exempt | United Biotech Pvt. Limited.India | Dreamax Incorporated | DRP-15223 | May 29, 2029 | |
Maxtaxel-80Docetaxel (as trihydrate) | 80 mg/2 mL Concentrate Solution for Injection10 mL-Type 1 Clear Borosilicate Tubular Glass Vial Sealed with Gray Butyl Rubber Stopper and Aluminum Flip-Off Seal Cap + 6 mL (net content) Diluents in 10 mL-Type 1 Clear Borosilicate Tubular Glass Vial Sealed with Gray Butyl Rubber Stopper and Aluminum Flip-Off Seal Cap (Box of 1's) | RxVAT-exempt | United Biotech Pvt. LimitedIndia | Dreamax Incorporated | DRP-15222 | May 29, 2029 | |
MydoceDocetaxel | 10 mg / mL Concentrate Solution for IV InfusionBox of 1-Type I flint tubular vial with grey bromobutyl rubber stopper and violet aluminum flip-off seal (2 mL, 8 mL, 16 mL) | RxVAT-exempt | Mylan Laboratories Limited- OTLIndia | Viatris Pharmaceuticals, Inc. | DRP-15817 | Jan 25, 2027 | |
MydoceDocetaxel | 10mg/mL Concentrate Solution for IV Infusion : AntineoplasticBox of 1-Type I flint tubular vial with grey bromobutyl rubber stopper and violet aluminum flip-off seal (2 mL, 8 mL, 16 mL) | RxVAT-exempt | Mylan Laboratories Limited - OTLIndia | Mylan Philippines Inc. | DR-XY47686 | Jan 25, 2027 | |
Newtaxel-ADocetaxel (as trihydrate) | 40 mg/mL Solution for I.V. Injection20 mg/0.5 mL: USP Type I Colorless Vial x 0.5 mL (active) + USP Type I Colorless Glass Vial x 1.8 mL (diluent) (Box of 1's); 80 mg/2 mL: USP Type I Colorless Vial x 2 mL (active) + USP Type I Colorless Glass Vial x 7 ml (diluent) (Box of 1's) | RxVAT-exempt | Korea United Pharm. Inc.Republic of Korea | Qualimed Pharma Inc. | DR-XY40517 | Jan 10, 2030 | |
NoneDocetaxel (as trihydrate) | 10 mg/mL (120 mg/12mL) Solution for Intravenous Infusion12 ml (fill volume) in 20 mL-capacity USP Type I clear glass vial with 20 mm bromobutyl stopper and 20 mm aluminum flip-off seal Box of 1's | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | Medethix, Inc. | DRP-9255 | Nov 11, 2028 | |
NoneDocetaxel (as trihydrate) | 10 mg/mL (20 mg/2 mL) Solution for Intravenous Infusion2 mL (fill volume) in 5 mL-capacity USP Type I clear glass vial with 20 mm bromobutyl stopper and 20 mm aluminum flip-off seal Box of 1's | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | MedEthix, Inc. | DRP-9259 | Nov 11, 2028 | |
NoneDocetaxel (as trihydrate) | 10 mg/mL (80 mg/ mL) Solution for Intravenous Infusion8 mL (fill volume) in 10 mL-capacity USP Type I clear glass vial with 20 mm bromobutyl stopper and 20 mm aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | MedEthix, Inc. | DRP-9257 | Nov 11, 2028 | |
NoneDocetaxel | 20 mg/mL Concentrate Solution for IV InfusionUSP Type I clear glass vial x 1 mL, 4 mL and 6 mL with rubber stopper and aluminum blue flip-off seal (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-15643 | Sep 13, 2029 | |
NoneDocetaxel (as trihydrate) | 20 mg/mL, 80 mg/4 mL and 120 mg/6 mL Concentrate Solution for IV InfusionUSP Type 1 clear glass vial in 1 mL, 4mL and 6mL (net content) (Box of 1's) | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-5795-01 | Nov 13, 2029 | |
noneDocetaxel | 20mg/0.5mL Concentration for injection (IV)USP Type I clear glass vial x 0.5mL with Diluent (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | MEDETHIX INC.Importer: I.E. Medica, Inc. | DRP-1486-01 | Oct 28, 2031 | |
NoneDocetaxel | 40 mg/mL Concentrate for Solution for IV InfusionUSP Type I Clear Glass Vial with Bromo-Butyl Stopper and Red Colored Flip-off Seal + Water for Injection (diluent) Box of 1 containing 15 mL vial x 2 mL (active) + 1 vial x 6 mL (Diluent); Box of 1 containing 20 mL vial x 3 mL (active) + 1 vial x 9 mL (Diluent) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix, Inc.Importer: I.E Medica, Inc. | DRP-6927-02 | Dec 19, 2026 | |
NoneDocetaxel | 40 mg/mL Concentrated Solution for IV InfusionUSP Type I Clear Glass Vial with Bromo-Butyl Stopper and Red Colored Flip-off Seal + Water for Injection (diluent) Box of 1 containing 15 mL vial x 2 mL (active) + 1 vial x 6 mL (Diluent); Box of 1 containing 20 mL vial x 3 mL (active) + 1 vial x 9 mL (Diluent) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix, Inc.Importer: I.E Medica, Inc. | DRP-6927-01 | Dec 19, 2026 | |
Novataxel-20Docetaxel | 40 mg/mL (20 mg/0.5 mL) Concentrate Solution for IV Infusion5 mL-Capacity USP Type I clear glass vial sealed with 20 mm Omniflex Rubber stopper and non-tear-off Aluminum Seal with Red Polypropylene Flip-Off Cap x 0.5 mL (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8581 | Dec 18, 2029 | |
Novataxel-80Docetaxel | 40 mg/mL (80 mg/2 mL) Concentrate Solution for IV Infusion15 mL-capacity USP Type I clear glass vial sealed with 20 mm omniflex rubber stopper and non-tear off aluminum seal with red polypropylene flip-off cap x 2 mL (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8580 | Dec 18, 2029 | |
Novotaxel 120Docetaxel (as trihydrate) | 10 mg/mL (120 mg/12 mL) Solution for Intravenous Infusion12 mL (fill volume) in 20 mL-capacity USP Type I clear glass vial with 20 mm bromobutyl stopper and 20 mm aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | MedEthix, Inc. | DRP-9256 | Nov 11, 2028 | |
Novotaxel 20Docetaxel (as trihydrate) | 10 mg/mL (20 mg/2 mL) Solution for Intravenous Infusion2 mL (fill volume) in 5 mL-capacity USP Type I clear glass vial with 20 mm bromobutyl stopper and 20 mm aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | MedEthix, Inc. | DRP-9260 | Nov 11, 2028 | |
Novotaxel 80Docetaxel (as trihydrate) | 10 mg/mL (80 mg/8 mL) Solution for Intravenous Infusion8 mL (fill volume) in 10 mL-capacity USP Type I clear glass vial with 20 mm bromobutyl stopper and 20 mm aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Therdose Pharma Pvt. Ltd.India | MedEthix, Inc. | DRP-9258 | Nov 11, 2028 | |
OcetaxDocetaxel | 20 mg/mL Concentrate Solution for IV InfusionIn 5-mL USP Type I clear vial with grey fluorotec rubber stopper and orange aluminum flip-off seal x 1 mL Box of 1's | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Oncolife CorporationImporter: Accord Healthcare Limited - Philippine Branch Office | DRP-8318-01 | Oct 17, 2029 | |
OcetaxDocetaxel | 80 mg/4 mL Concentrate Solution for IV InfusionIn 5 mL-USP Type I clear vial with grey fluorotec rubber stopper and red aluminum flip-off seal x 4 mL (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | ONCOLIFE CORPORATIONImporter: Accord Healthcare Limited - Philippine Branch Office | DRP-8317-02 | Oct 19, 2029 | |
Olletaxel-10Docetaxel | 10 mg/mL Concentrate Solution for Injection (IV Infusion)Type 1 Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Non-Tear Off Aluminum Seal with Polypropylene Flip-Off Cap x 2 mL, 8 mL, 12 mL, and 16 mL (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Ollen Pharma Trading, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-15277 | Jun 4, 2029 | |
Olletaxel-40Docetaxel | 40 mg/mL (120 mg/3 mL) Concentrate Solution for Injection (IV Infusion)Type 1 Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Non-Tear Off Aluminum Seal with PP Flip-Off Cap x 3 mL + Sterile Water for Injection. in Type I Clear Glass Vial x 9 mL (Diluent) (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Ollen Pharma Trading, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-15278 | Jun 4, 2029 | |
Revataxel 20Docetaxel (as trihydrate) | 40 mg/mL (20 mg/0.5 mL) Concentrated Solution for IV Infusion5 mL-capacity Type I clear glass vial x 0.5 mL (net content) with bromobutyl rubber stopper, aluminum seal and orange flip-off cap + 1 vial diluent x 1.5 mL (net content) in a plastic tray (Box of 1 finished product and 1 diluent) | RxVAT-exempt | Revacure Lifesciences LLPIndia | Biocare Lifesciences, Inc. | DRP-17466 | Jan 6, 2031 | |
SaphdocetDocetaxel | 20mg/0.5mL (40mg/mL) Concentrate Solution for Injection (IV Infusion)5mL-Capacity Type I Flint Vial Sealed with Gray Butyl Rubber Stopper and Aluminum Seal with PP Flip-Off Cap x 0.5mL (Net content) + 1.5mL Sterile Water for Injection in Clear Glass Vial in PVC Tray (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc. | DRP-17578 | Feb 4, 2031 | |
SaphdocetDocetaxel | 40 mg/mL (20 mg/0.5 mL and 80 mg/2 mL) Concentrate Solution for Intravenous InfusionUSP Type I clear glass vial with butyl rubber stopper, aluminum seal and PP flip-off cap + 1 ampoule x 2 mL water for injection (diluent) (Box of 1 vial of finished product and 1 ampoule of diluent) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-16724 | Jul 1, 2030 | |
SaphdocetDocetaxel | 40mg/mL (80mg/2mL) Concentrate Injection (IV Infusion)15mL-Capacity Type I Flint Vial Sealed with Gray Butyl Rubber Stopper and Aluminum Seal with PP Flip-Off Cap x 2mL (Net content) + 6mL Sterile Water for Injection in Clear Glass Vial in PVC Tray (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc. | DRP-17579 | Feb 4, 2031 | |
Taceedo 20Docetaxel (as Trihydrate) | 40 mg/mL (20 mg/0.5 mL) Concentrated Solution for IV Infusion0.5 mL (net content) in 5 mL Type I Flint Vial in Carbon Box + Vial containing 1.5 mL Solvent in Carbon Box (Box of 1's) | RxVAT-exempt | Naprod Life Sciences Pvt. Ltd.India | Multicare Pharmaceuticals Phils.,Inc.Importer: Multicare Pharmaceuticals Phils., Inc. | DRP-10396 | Jan 13, 2031 | |
Taceedo 80Docetaxel (as Trihydrate) | 40 mg/mL (80 mg/2 mL) Concentrated Solution for IV Infusion2 mL (net content) in 10 mL Type I Flint Vial in carbon box + Vial containing 6 mL Solvent in Carbon box ( Box of 1's) | RxVAT-exempt | Naprod Life Sciences Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc. | DRP-10544 | Jan 12, 2031 | |
TaxelidoDocetaxel (as trihydrate) | 20 mg/mL (80 mg/4mL) Solution for IV infusion.USP Type I clear glass vial with rubber stopper and a aluminum red flip-off seal with polypropylene cap x 4mL (Box of 1's) | RxVAT-exempt | PT. CKD Otto PharmaceuticalsIndonesia | JLT Pharma Inc. | DRP-15272 | Jun 4, 2029 | |
TaxelidoDocetaxel (as trihydrate) | 20 mg/mL Solution for IV InfusionUSP Type I clear glass vial with rubber stopper and aluminum green flip-off seal with polypropylene cap x 1mL (Box of 1's) | RxVAT-exempt | PT. CKD Otto PharmaceuticalsIndonesia | JLT Pharma Inc. | DRP-15274 | Jun 4, 2029 | |
TaxeriaDocetaxel (as trihydrate) | 20 mg/0.5 mL Concentrate Solution for I.V. InfusionOne (1) box contains: USP Type I flint glass vial in 0.5 mL (net content as active) + USP Type I flint glass vial in 1.5mL (net content as diluent) in a plastic tray. (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Pharma 518, Inc.Importer: Ambica International Corporation | DRP-5972-01 | Jan 28, 2030 | |
TaxeriaDocetaxel (as trihydrate) | 80 mg/2 mL Concentrate Solution for I.V. InfusionUSP Type I Flint Glass Vial in 2 mL (net content as active) + USP Type I Flint Glass Vial in 6 mL (net content as diluent) in a plastic tray (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Pharma 518, Inc.Importer: Ambica International Corporation | DRP-5973-02 | Jan 28, 2030 | |
TaxewellDocetaxel (as trihydrate) | 120 mg/3 mL Concentrate Solution for I.V. InfusionOne (1) box contains: USP Type I flint glass vial in 3 mL (net content as active) + USP Type I flint glass vial in 9 mL (net content as diluent) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambica International Corporation | DRP-5971 | Jan 28, 2030 | |
TaxewellDocetaxel (as trihydrate) | 20 mg/0.5 mL Concentrate Solution for I.V. InfusionOne (1) box contains: USP Type I flint glass vial in 0.5 mL (net content as active) + USP Type I flint glass vial in 1.5mL (net content as diluent) in a plastic tray. (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambica International Corporation | DRP-5972 | Jan 28, 2030 | |
TaxewellDocetaxel (as trihydrate) | 80 mg/2 mL Concentrate Solution for I.V. InfusionOne (1) box contains: USP Type I Flint Glass Vial in 2 mL (net content as active) + USP Type I Flint Glass Vial in 6 mL (net content as diluent) in a plastic tray. | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambica International Corporation | DRP-5973 | Jan 28, 2030 | |
TaxogenDocetaxel | 40 mg/mL (20 mg/0.5 mL) Concentrate Solution for IV Infusion"5 mL-Capacity USP Type I clear glass vial sealed with 20 mm Omniflex Rubber stopper and non-tear-off Aluminum Seal with Red Polypropylene Flip-Off Cap x 0.5 mL" (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Genace Pharma DistributorImporter: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8581-02 | Dec 18, 2029 | |
TaxogenDocetaxel | 40 mg/mL (80 mg/2 mL) Concentrate Solution for IV Infusion15 mL-capacity USP Type I clear glass vial sealed with 20 mm Omniflex Rubber Stopper and non-tear off Aluminum Seal with Red Polypropylene Flip-off Cap x 2 mL (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Genace Pharma DistributorImporter: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Pvt. Ltd. | DRP-8580-02 | Dec 18, 2029 | |
TaxotereDocetaxel (as trihydrate) | 20 mg/mL Concentrate for Solution for IV InfusionIn a box of 1 clear blister clamshell packaging containing 7 mL clear glass vial (type I) closed with EIFE coated grey coloured bromobutyl rubber stopper crimped to the vial by a green aluminum cap covered with a light green plastic flip-off cap | RxVAT-exempt | Sanofi-Aventis Deutschland GmbHGermany | Importer: sanofi-aventis Philippines, Inc. | DR-XY40953 | Sep 17, 2030 | |
TaxotereDocetaxel (as trihydrate) | 80 mg/4 mL Concentrate for Solution for IV InfusionIn a box of 1 of clear blister clamshell packaging containing 7 mL clear glass vial (type I) closed with an EIFE coated grey coloured bromobutyl rubber stopper crimped to the vial by a red aluminum cap covered with a magenta plastic flip-off cap | RxVAT-exempt | Sanofi-Aventis Deutschland GmbHGermany | Importer: sanofi-aventis Philippines, Inc. | DR-XY40952 | Sep 17, 2030 | |
Taxtas 20Docetaxel | 20 mg/mL Concentrate Solution for IV InfusionIn 5-mL USP Type I clear vial with grey fluorotec rubber stopper and orange aluminum flip-off seal x 1 mL (Box of 1) | RxVAT-exempt | INTAS PHARMACEUTICALS LIMITEDIndia | Accord Healthcare Limited - Philippine Branch Office | DRP-8318 | Oct 17, 2029 | |
Taxtas 80Docetaxel | 80mg/4mL Concentrate Solution for IV InfusionIn 5mL- USP Type I clear vial with grey fluorotec rubber stopper and red aluminum flip-off seal x 4 mL Box of 1's | RxVAT-exempt | INTAS PHARMACEUTICALS LIMITEDIndia | Accord Healthcare Limited - Philippine Branch Office | DRP-8317 | Oct 19, 2029 | |
UnbrandedDocetaxel (as Trihydrate) | 20 mg/0.5 ml Concentrated Solution for Injection (I.V. Infusion)0.5 mL in 5 mL Amber Glass Vial USP Type I + 1.5 mL Absolute Alcohol (as solvent) in 5 mL Flint Glass Vial Type I Box of 1 's | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-5700-01 | Nov 10, 2029 | |
Unidocet-20Docetaxel (as trihydrate) | 20 mg/0.5 mL Concentrate for Solution for IV InfusionBox of 1 containing 5 mL-Capacity USP Type I Clear Glass Vial with Grey Bromo Butyl Rubber Stopper and Grey colored Flip-Off Seal x 0.5 mL (net content) and 1.5 mL net content Absolute alcohol (Diluent) in 5 mL USP Type I Clear Glass Vial with Grey Bromo Butyl Rubber Stopper and Green colored Flip-Off Seal | RxVAT-exempt | ADMAC LifesciencesIndia | AGB Pharmaceutical Trading and Consultancy Corporation | DRP-12719 | Sep 28, 2027 | |
Unidocet-80Docetaxel trihydrate | 40 mg/mL (80 mg/2 mL) Concentrate Solution for IVIn 1 Box contains: 10 mL-Capacity USP Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Yellow Aluminum Flip-Off Seal x 2 mL (net content) and Diluent in 10 mL-Capacity USP Type I Clear Glass Vial with Bromobutyl Rubber Stopper and White Aluminum Flip-Off Seal x 6 mL (net content) | RxVAT-exempt | Admac LifesciencesIndia | AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-13734 | Apr 3, 2028 | |
Vexdo 20Docetaxel (as trihydrate) | 40 mg/mL (20 mg/0.5 mL) Solution for Injextion (I.V Infusion)0.5 mL (net content) in 5 mL -capacity USP Type I clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with gray flip-off cap + 1.5 mL(net content) in 5 mL-capacity USP Type I clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with green flip-off cap as diluent in plastic tray (Box of 1 vial + 1 vial diluent) | RxVAT-exempt | Admac LifesciencesIndia | VE Pharma, Inc.Trader: Vexxa Lifesciences Pvt. Ltd | DR-XY44389 | Mar 26, 2030 | |
Vexdo 80Docetaxel (as trihydrate) | 40 mg/mL (80 mg/2 mL) Solution for Injection (I.V. Infusion)2 mL (net content) in 10 mL-capacity USP Type I clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with yellow flip-off cap + 6 mL ( net content) in 10 mL-capacity USP Type I clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with white flip-off cap as diluent in plastic tray (Box of 1 vial + 1 vial diluent) | RxVAT-exempt | Admac LifesciencesIndia | VE Pharma, Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY44388 | Mar 26, 2030 | |
ZycuronDocetaxel | 40 mg/mL (80 mg/2 mL) Concentrate Solution for IV InfusionUSP Type I Amber Glass Vial with Red Flip-Off Seal × 10 mL (2 mL net content) + USP Type I Amber Glass Vial with Green Flip-Off Seal Solvent × 10 mL (6 mL net content) in PVC Tray (Box of 1's) | RxVAT-exempt | Kwality Pharmaceuticals LimitedIndia | Pharma-Surrey International Inc.Trader: N/A | DRP-17167 | Oct 10, 2030 | |
(no brand name)Docetaxel | 10 mg/mL Solution for Infusion (IV)Type I Clear and Colorless Glass Vial x 2 mL and 8 mL (Box of 1's) | RxVAT-exempt | Zydus-Hozpira Oncology Private Ltd.India | Importer: Pfizer, Inc. | DR-XY39743 | Oct 17, 2029 | |
(no brand name)Docetaxel | 20 mg/mL (80 mg / 4 mL) Concentrate For Solution For IV Infusion15 mL Type I Tubular Clear Glass Vial with Rubber Stopper and Aluminum Flip-off Seal (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY48219 | Jul 22, 2027 | |
(no brand name)Docetaxel | 20 mg/mL Concentrate Solution for I.V. Infusion5 mL Type I clear glass vial enclosed with gray bromobutyl rubber stopper and aluminum seal with polypropylene green flip-off cap (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY48721 | May 8, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: One-vial Docetaxel: Single-dose vials 20 mg/mL, 80 mg/4 mL and 160 mg/8 mL (3) One-vial Docetaxel (Injection) Docetaxel 20 mg/mL Docetaxel injection 20 mg/1 mL single-dose vial: 20 mg docetaxel in 1 mL 50/50 (v/v) ratio polysorbate 80/dehydrated alcohol. Docetaxel 80 mg/4 mL Docetaxel injection 80 mg/4 mL single-dose vial: 80 mg docetaxel in 4 mL 50/50 (v/v) ratio polysorbate 80/dehydrated alcohol. Docetaxel 160 mg/8 mL Docetaxel injection 160 mg/8 mL single-dose vial: 160 mg docetaxel in 8 mL 50/50 (v/v) ratio polysorbate 80/dehydrated alcohol.
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Second primary malignancies: In patients treated with Docetaxel-containing regimens, monitor for delayed AML, MDS, NHL, and renal cancer. (5.7)
- Cutaneous reactions: Reactions including erythema of the extremities with edema followed by desquamation may occur. Severe cutaneous adverse reactions have been reported. Severe skin toxicity may require dose adjustment or permanent treatment discontinuation. (5.8)
- Neurologic reactions: Reactions including paresthesia, dysesthesia, and pain may occur. Severe neurosensory symptoms require dose adjustment or discontinuation if persistent. (5.9)
- Eye disorders: Cystoid macular edema (CME) has been reported and requires treatment discontinuation. (5.10)
- Asthenia: Severe asthenia may occur and may require treatment discontinuation. (5.11)
- Embryo-fetal toxicity: Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. (5.12, 8.1, 8.3)
- Alcohol content: The alcohol content in a dose of Docetaxel injection may affect the central nervous system. This may include impairment of a patient's ability to drive or use machines immediately after infusion. (5.13)
- Tumor lysis syndrome: Tumor lysis syndrome has been reported. Patients at risk should be well hydrated and closely monitored during treatment. (5.14)
5.1 Toxic Deaths Breast Cancer
5.1 Toxic Deaths Breast Cancer Docetaxel administered at 100 mg/m 2 was associated with deaths considered possibly or probably related to treatment in 2.0% (19/965) of metastatic breast cancer patients, both previously treated and untreated, with normal baseline liver function and in 11.5% (7/61) of patients with various tumor types who had abnormal baseline liver function (AST and/or ALT >1.5 times ULN together with AP >2.5 times ULN). Among patients dosed at 60 mg/m 2, mortality related to treatment occurred in 0.6% (3/481) of patients with normal liver function, and in 3 of 7 patients with abnormal liver function.
Approximately half of these deaths occurred during the first cycle. Sepsis accounted for the majority of the deaths. Non-small Cell Lung Cancer Docetaxel administered at a dose of 100 mg/m 2 in patients with locally advanced or metastatic non-small cell lung cancer who had a history of prior platinum-based chemotherapy was associated with increased treatment-related mortality (14% and 5% in two randomized, controlled studies).
There were 2.8% treatment-related deaths among the 176 patients treated at the 75 mg/m 2 dose in the randomized trials. Among patients who experienced treatment-related mortality at the 75 mg/m 2 dose level, 3 of 5 patients had an ECOG PS of 2 at study entry [see Dosage and Administration (2.2), Clinical Studies (14)].
5.2 Hepatic Impairment
5.2 Hepatic Impairment Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Avoid docetaxel in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN [see Warnings and Precautions (5.1)].
For patients with isolated elevations of transaminase >1.5 × ULN, consider docetaxel dose modifications [see Dosage and Administration (2.7)]. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of docetaxel therapy.
5.3 Hematologic Effects
5.3 Hematologic Effects Perform frequent peripheral blood cell counts on all patients receiving docetaxel. Do not retreat patients with subsequent cycles of docetaxel until neutrophils recover to a level >1500 cells/mm 3 [see Contraindications (4)]. Avoid retreating patients until platelets recover to a level >100,000 cells/mm 3.
A 25% reduction in the dose of docetaxel is recommended during subsequent cycles following severe neutropenia (<500 cells/mm 3) lasting 7 days or more, febrile neutropenia, or a grade 4 infection in a docetaxel cycle [see Dosage and Administration (2.7)]. Neutropenia (<2000 neutrophils/mm 3) occurs in virtually all patients given 60 mg/m 2 to 100 mg/m 2 of docetaxel and grade 4 neutropenia (<500 cells/mm 3) occurs in 85% of patients given 100 mg/m 2 and 75% of patients given 60 mg/m 2.
Frequent monitoring of blood counts is, therefore, essential so that dose can be adjusted. Docetaxel should not be administered to patients with neutrophils <1500 cells/mm 3. Febrile neutropenia occurred in about 12% of patients given 100 mg/m 2 but was very uncommon in patients given 60 mg/m 2. Hematologic responses, febrile reactions and infections, and rates of septic death for different regimens are dose related [see Adverse Reactions (6.1), Clinical Studies (14)].
Three breast cancer patients with severe liver impairment (bilirubin >1.7 times ULN) developed fatal gastrointestinal bleeding associated with severe drug-induced thrombocytopenia. In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not.
Patients receiving TCF should be closely monitored during the first and subsequent cycles for febrile neutropenia and neutropenic infection [see Dosage and Administration (2.7), Adverse Reactions (6)].
5.4 Enterocolitis and Neutropenic Colitis
5.4 Enterocolitis and Neutropenic Colitis Enterocolitis and neutropenic colitis (typhlitis) have occurred in patients treated with docetaxel alone and in combination with other chemotherapeutic agents, despite the coadministration of G-CSF. Caution is recommended for patients with neutropenia, particularly at risk for developing gastrointestinal complications.
Enterocolitis and neutropenic enterocolitis may develop at any time, and could lead to death as early as the first day of symptom onset. Monitor patients closely from onset of any symptoms of gastrointestinal toxicity. Inform patients to contact their healthcare provider with new, or worsening symptoms of gastrointestinal toxicity [see Dosage and Administration (2), Warnings and Precautions (5.3), Adverse Reactions (6.2)].
5.5 Hypersensitivity Reactions
5.5 Hypersensitivity Reactions Monitor patients closely for hypersensitivity reactions, especially during the first and second infusions. Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids.
Severe hypersensitivity reactions require immediate discontinuation of the docetaxel infusion and aggressive therapy. Do not rechallenge patients with a history of severe hypersensitivity reactions with docetaxel [see Contraindications (4)]. Patients who have previously experienced a hypersensitivity reaction to paclitaxel may develop a hypersensitivity reaction to docetaxel that may include severe or fatal reactions such as anaphylaxis.
Monitor patients with a previous history of hypersensitivity to paclitaxel closely during initiation of docetaxel therapy. Hypersensitivity reactions may occur within a few minutes following initiation of a docetaxel infusion. If minor reactions such as flushing or localized skin reactions occur, interruption of therapy is not required.
All patients should be premedicated with an oral corticosteroid prior to the initiation of the infusion of docetaxel [see Dosage and Administration (2.6)].
5.6 Fluid Retention
5.6 Fluid Retention Severe fluid retention has been reported following docetaxel therapy. Patients should be premedicated with oral corticosteroids prior to each docetaxel administration to reduce the incidence and severity of fluid retention [see Dosage and Administration (2.6)]. Patients with pre-existing effusions should be closely monitored from the first dose for the possible exacerbation of the effusions.
When fluid retention occurs, peripheral edema usually starts in the lower extremities and may become generalized with a median weight gain of 2 kg. Among 92 breast cancer patients premedicated with 3-day corticosteroids, moderate fluid retention occurred in 27.2% and severe fluid retention in 6.5%. The median cumulative dose to onset of moderate or severe fluid retention was 819 mg/m 2.
Nine of 92 patients (9.8%) of patients discontinued treatment due to fluid retention: 4 patients discontinued with severe fluid retention; the remaining 5 had mild or moderate fluid retention. The median cumulative dose to treatment discontinuation due to fluid retention was 1021 mg/m 2. Fluid retention was completely, but sometimes slowly, reversible with a median of 16 weeks from the last infusion of docetaxel to resolution (range: 0 to 42+ weeks).
Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s).
5.7 Second Primary Malignancies
5.7 Second Primary Malignancies Second primary malignancies, notably acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), and renal cancer, have been reported in patients treated with docetaxel-containing regimens. These adverse reactions may occur several months or years after docetaxel-containing therapy.
Treatment-related AML or MDS has occurred in patients given anthracyclines and/or cyclophosphamide, including use in adjuvant therapy for breast cancer. In the adjuvant breast cancer trial (TAX316) AML occurred in 3 of 744 patients who received docetaxel, doxorubicin and cyclophosphamide (TAC) and in 1 of 736 patients who received fluorouracil, doxorubicin, and cyclophosphamide [see Clinical Studies (14.2)].
In TAC-treated patients, the risk of delayed myelodysplasia or myeloid leukemia requires hematological follow-up. Monitor patients for second primary malignancies [see Adverse Reactions (6.1)].
5.8 Cutaneous Reactions
5.8 Cutaneous Reactions Localized erythema of the extremities with edema followed by desquamation has been observed. In case of severe skin toxicity, an adjustment in dosage is recommended [see Dosage and Administration (2.7)]. The discontinuation rate due to skin toxicity was 1.6% (15/965) for metastatic breast cancer patients.
Among 92 breast cancer patients premedicated with 3-day corticosteroids, there were no cases of severe skin toxicity reported and no patient discontinued docetaxel due to skin toxicity. Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP) have been reported in association with docetaxel treatment.
Patients should be informed about the signs and symptoms of serious skin manifestations and monitored closely. Permanent treatment discontinuation should be considered in patients who experience SCARs.
5.9 Neurologic Reactions
5.9 Neurologic Reactions Severe neurosensory symptoms (e.g. paresthesia, dysesthesia, pain) were observed in 5.5% (53/965) of metastatic breast cancer patients, and resulted in treatment discontinuation in 6.1%. When these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be discontinued [see Dosage and Administration (2.7)].
Patients who experienced neurotoxicity in clinical trials and for whom follow-up information on the complete resolution of the event was available had spontaneous reversal of symptoms with a median of 9 weeks from onset (range: 0 to 106 weeks). Severe peripheral motor neuropathy mainly manifested as distal extremity weakness occurred in 4.4% (42/965).
5.10 Eye Disorders
5.10 Eye Disorders Cystoid macular edema (CME) has been reported in patients treated with docetaxel. Patients with impaired vision should undergo a prompt and comprehensive ophthalmologic examination. If CME is diagnosed, docetaxel treatment should be discontinued and appropriate treatment initiated. Alternative non-taxane cancer treatment should be considered.
5.11 Asthenia
5.11 Asthenia Severe asthenia has been reported in 14.9% (144/965) of metastatic breast cancer patients but has led to treatment discontinuation in only 1.8%. Symptoms of fatigue and weakness may last a few days up to several weeks and may be associated with deterioration of performance status in patients with progressive disease.
5.12 Embryo-Fetal Toxicity
5.12 Embryo-Fetal Toxicity Based on findings from animal reproduction studies and its mechanism of action, docetaxel can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. Available data from case reports in the literature and pharmacovigilance with docetaxel use in pregnant women are not sufficient to inform the drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
In animal reproduction studies, administration of docetaxel to pregnant rats and rabbits during the period of organogenesis caused embryo-fetal toxicities, including intrauterine mortality, at doses as low as 0.02 and 0.003 times the recommended human dose based on body surface area, respectively. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
Verify pregnancy status in females of reproductive potential prior to initiating docetaxel. Advise females of reproductive potential to use effective contraception during treatment and for 2 months after the last dose of docetaxel. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the last dose of docetaxel [see Use in Specific Populations (8.1, 8.3)].
5.13 Alcohol Content
5.13 Alcohol Content Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content. The alcohol content in a dose of Docetaxel injection may affect the central nervous system and should be taken into account for patients in whom alcohol intake should be avoided or minimized. Consideration should be given to the alcohol content in Docetaxel injection on the ability to drive or use machines immediately after the infusion.
Each administration of Docetaxel injection at 100 mg/m 2 delivers 2.0 g/m 2 of ethanol. For a patient with a BSA of 2.0 m², this would deliver 4.0 grams of ethanol [see Description (11)]. Other docetaxel products may have a different amount of alcohol.
5.14 Tumor Lysis Syndrome
5.14 Tumor Lysis Syndrome Tumor lysis syndrome has been reported with docetaxel [see Adverse Reactions (6.2)]. Patients at risk of tumor lysis syndrome (e.g., with renal impairment, hyperuricemia, bulky tumor) should be closely monitored prior to initiating docetaxel and periodically during treatment. Correction of dehydration and treatment of high uric acid levels are recommended prior to initiation of treatment.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Docetaxel is a CYP3A4 substrate. In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4. In vivo studies showed that the exposure of docetaxel increased 2.2-fold when it was coadministered with ketoconazole, a potent inhibitor of CYP3A4.
Protease inhibitors, particularly ritonavir, may increase the exposure of docetaxel. Concomitant use of docetaxel and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. In patients receiving treatment with docetaxel, close monitoring for toxicity and a docetaxel dose reduction could be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided [see Dosage and Administration (2.7), Clinical Pharmacology (12.3)].
Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (7)
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metabolism Docetaxel is metabolized by the CYP3A4 isoenzyme in vitro [see Drug Interactions (7) ] .
Drug Interaction Studies Effect of Ketoconazole: The effect of ketoconazole (a strong CYP3A4 inhibitor) on the pharmacokinetics of docetaxel was investigated in 7 cancer patients.
7 DRUG INTERACTIONS Docetaxel is a CYP3A4 substrate.
In vivo studies showed that the exposure of docetaxel increased 2.2-fold when it was coadministered with ketoconazole, a potent inhibitor of CYP3A4.
Concomitant use of docetaxel and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided.
In patients receiving treatment with docetaxel, close monitoring for toxicity and a docetaxel dose reduction could be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided [see Dosage and Administration (2.7) , Clinical Pharmacology (12.3) ] .
Adverse reactions
The most serious adverse reactions from docetaxel are: Toxic Deaths [see Boxed Warning, Warnings and Precautions (5.1)] Hepatic Impairment [see Boxed Warning, Warnings and Precautions (5.2)] Hematologic Effects [see Boxed Warning, Warnings and Precautions (5.3)] Enterocolitis and Neutropenic Colitis [see Warnings and Precautions (5.4)] Hypersensitivity Reactions [see Boxed Warning, Warnings and Precautions (5.5)] Fluid Retention [see Boxed Warning, Warnings and Precautions (5.6)] Second Primary Malignancies [see Warnings and Precautions (5.7)] Cutaneous Reactions [see Warnings and Precautions (5.8)] Neurologic Reactions [see Warnings and Precautions (5.9)] Eye Disorders [see Warnings and Precautions (5.10)] Asthenia [see Warnings and Precautions (5.11)] Alcohol Content [see Warnings and Precautions (5.13)] The most common adverse reactions across all docetaxel indications are infections, neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions, and myalgia. Incidence varies depending on the indication.
Adverse reactions are described according to indication. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the …
6.1 Clinical Trials Experience Breast Cancer
6.1 Clinical Trials Experience Breast Cancer Monotherapy with docetaxel for locally advanced or metastatic breast cancer after failure of prior chemotherapy Docetaxel 100 mg/m 2: Adverse drug reactions occurring in at least 5% of patients are compared for three populations who received docetaxel administered at 100 mg/m 2 as a 1-hour infusion every 3 weeks: 2045 patients with various tumor types and normal baseline liver function tests; the subset of 965 patients with locally advanced or metastatic breast cancer, both previously treated and untreated with chemotherapy, who had normal baseline liver function tests; and an additional 61 patients with various tumor types who had abnormal liver function tests at baseline. These reactions were described using COSTART terms and were considered possibly or probably related to docetaxel.
At least 95% of these patients did not receive hematopoietic support. The safety profile is generally similar in patients receiving docetaxel for the treatment of breast cancer and in patients with other tumor types. (See Table 3.) Table 3: Summary of Adverse Reactions in Patients Receiving Docetaxel at 100 mg/m 2 Adverse Reaction All Tumor Types Normal LFTs Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN n=2045 % All Tumor Types Elevated LFTs Elevated Baseline LFTs: AST and/or ALT >1.5 times ULN concurrent with alkaline phosphatase >2.5 times ULN n=61 % Breast Cancer Normal LFTs n=965 % Hematologic Neutropenia <2000 cells/mm 3 96 96 99 <500 cells/mm 3 75 88 86 Leukopenia <4000 cells/mm 3 96 98 99 <1000 cells/mm 3 32 47 44 Thrombocytopenia <100,000 cells/mm 3 8 25 9 Anemia <11 g/dL 90 92 94 <8 g/dL 9 31 8 Febrile Neutropenia Febrile Neutropenia: ANC grade 4 with fever >38°C with intravenous antibiotics and/or hospitalization 11 26 12 Septic Death 2 5 1 Non-Septic Death 1 7 1 Infections Any 22 33 22 Severe 6 16 6 Fever in Absence of Infection Any 31 41 35 Severe 2 8 2 Hypersensitivity Reactions Regardless of Premedication Any 21 20 18 Severe 4 10 3 With 3-day Premedication n=92 n=3 n=92 Any 15 33 15 Severe 2 0 2 Fluid Retention Regardless of Premedication Any 47 39 60 Severe 7 8 9 With 3-day Premedication n=92 n=3 n=92 Any 64 67 64 Severe 7 33 7 Neurosensory Any 49 34 58 Severe 4 0 6 Cutaneous Any 48 54 47 Severe 5 10 5 Nail Changes Any 31 23 41 Severe 3 5 4 Gastrointestinal Nausea 39 38 42 Vomiting 22 23 23 Diarrhea 39 33 43 Severe 5 5 6 Stomatitis Any 42 49 52 Severe 6 13 7 Alopecia 76 62 74 Asthenia Any 62 53 66 Severe 13 25 15 Myalgia Any 19 16 21 Severe 2 2 2 Arthralgia 9 7 8 Infusion Site Reactions 4 3 4 Hematologic reactions Reversible marrow suppression was the major dose-limiting toxicity of docetaxel [see Warnings and Precautions (5.3)].
The median time to nadir was 7 days, while the median duration of severe neutropenia (<500 cells/mm 3) was 7 days. Among 2045 patients with solid tumors and normal baseline LFTs, severe neutropenia occurred in 75.4% and lasted for more than 7 days in 2.9% of cycles. Febrile neutropenia (<500 cells/mm 3 with fever >38°C with intravenous antibiotics and/or hospitalization) occurred in 11% of patients with solid tumors, in 12.3% of patients with metastatic breast cancer, and in 9.8% of 92 breast cancer patients premedicated with 3-day corticosteroids.
Severe infectious episodes occurred in 6.1% of patients with solid tumors, in 6.4% of patients with metastatic breast cancer, and in 5.4% of 92 breast cancer patients premedicated with 3-day corticosteroids. Thrombocytopenia (<100,000 cells/mm 3) associated with fatal gastrointestinal hemorrhage has been reported. Hypersensitivity reactions Severe hypersensitivity reactions have been reported [see Boxed Warning, Warnings and Precautions (5.5)].
Minor events, including flushing, rash with or without pruritus, chest tightness, back pain, dyspnea, drug fever, or chills, have been reported and resolved after discontinuing the infusion and instituting appropriate therapy. Fluid retention Fluid retention can occur with the use of docetaxel [see Boxed Warning, Dosage and Administration (2.6), Warnings and Precautions (5.6)].
Cutaneous reactions Severe skin toxicity is discussed elsewhere in the label [see Warnings and Precautions (5.8)]. Reversible cutaneous reactions characterized by a rash including localized eruptions, mainly on the feet and/or hands, but also on the arms, face, or thorax, usually associated with pruritus, have been observed.
Eruptions generally occurred within 1 week after docetaxel infusion, recovered before the next infusion, and were not disabling. Severe nail disorders were characterized by hypo or hyperpigmentation, and occasionally by onycholysis (in 0.8% of patients with solid tumors) and pain. Neurologic reactions Neurologic reactions are discussed elsewhere in the label [see Warnings and Precautions (5.9)].
Gastrointestinal reactions Nausea, vomiting, and diarrhea were generally mild to moderate. Severe reactions occurred in 3%–5% of patients with solid tumors and to a similar extent among metastatic breast cancer patients. The incidence of severe reactions was 1% or less for the 92 breast cancer patients premedicated with 3-day corticosteroids.
Severe stomatitis occurred in 5.5% of patients with solid tumors, in 7.4% of patients with metastatic breast cancer, and in 1.1% of the 92 breast cancer patients premedicated with 3-day corticosteroids. Cardiovascular reactions Hypotension occurred in 2.8% of patients with solid tumors; 1.2% required treatment. Clinically meaningful events such as heart failure, sinus tachycardia, atrial flutter, dysrhythmia, unstable angina, pulmonary edema, and hypertension have occurred.
Seven of 86 (8.1%) of metastatic breast cancer patients receiving docetaxel 100 mg/m 2 in a randomized trial and who had serial left ventricular ejection fractions assessed developed deterioration of LVEF by ≥10% associated with a drop below the institutional lower limit of normal. Infusion site reactions Infusion site reactions were generally mild and consisted of hyperpigmentation, inflammation, redness or dryness of the skin, phlebitis, extravasation, or swelling of the vein.
Hepatic reactions In patients with normal LFTs at baseline, bilirubin values greater than the ULN occurred in 8.9% of patients. Increases in AST or ALT >1.5 times the ULN, or alkaline phosphatase >2.5 times ULN, were observed in 18.9% and 7.3% of patients, respectively. While on docetaxel, increases in AST and/or ALT >1.5 times ULN concomitant with alkaline phosphatase >2.5 times ULN occurred in 4.3% of patients with normal LFTs at baseline.
Whether these changes were related to the drug or underlying disease has not been established. Hematologic and other toxicity: Relation to dose and baseline liver chemistry abnormalities Hematologic and other toxicity is increased at higher doses and in patients with elevated baseline liver function tests (LFTs). In the following tables, adverse drug reactions are compared for three populations: 730 patients with normal LFTs given docetaxel at 100 mg/m 2 in the randomized and single arm studies of metastatic breast cancer after failure of previous chemotherapy; 18 patients in these studies who had abnormal baseline LFTs (defined as AST and/or ALT >1.5 times ULN concurrent with alkaline phosphatase >2.5 times ULN); and 174 patients in Japanese studies given docetaxel at 60 mg/m 2 who had normal LFTs (see Tables 4 and 5).
Table 4: Hematologic Adverse Reactions in Breast Cancer Patients Previously Treated with Chemotherapy Treated at Docetaxel 100 mg/m 2 with Normal or Elevated Liver Function Tests or 60 mg/m 2 with Normal Liver Function Tests Docetaxel 100 mg/m 2 Docetaxel 60 mg/m 2 Adverse Reaction Normal LFTs Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN n=730 % Elevated LFTs Elevated Baseline LFTs: AST and/or ALT >1.5 times ULN concurrent with alkaline phosphatase >2.5 times ULN n=18 % Normal LFTs n=174 % Neutropenia Any <2000 cells/mm 3 98 100 95 Grade 4 <500 cells/mm 3 84 94 75 Thrombocytopenia Any <100,000 cells/mm 3 11 44 14 Grade 4 <20,000 cells/mm 3 1 17 1 Anemia <11 g/dL 95 94 65 Infection Incidence of infection requiring hospitalization and/or intravenous antibiotics was 8.5% (n=62) among the 730 patients with normal LFTs at baseline; 7 patients had concurrent grade 3 neutropenia, and 46 patients had grade 4 neutropenia. Any 23 39 1 Grade 3 and 4 7 33 0 Febrile Neutropenia Febrile Neutropenia: For 100 mg/m 2, ANC grade 4 and fever >38°C with intravenous antibiotics and/or hospitalization; for 60 mg/m 2, ANC grade 3/4 and fever >38.1°C By Patient 12 33 0 By Course 2 9 0 Septic Death 2 6 1 Non-Septic Death 1 11 0 Table 5: Non-hematologic Adverse Reactions in Breast Cancer Patients Previously Treated with Chemotherapy Treated at Docetaxel 100 mg/m 2 with Normal or Elevated Liver Function Tests or 60 mg/m 2 with Normal Liver Function Tests Docetaxel 100 mg/m 2 Docetaxel 60 mg/m 2 Adverse Reaction Normal LFTs Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN n=730 % Elevated LFTs Elevated Baseline Liver Function: AST and/or ALT >1.5 times ULN concurrent with alkaline phosphatase >2.5 times ULN n=18 % Normal LFTs n=174 % NA = not available Acute Hypersensitivity Reaction Regardless of Premedication Any 13 6 1 Severe 1 0 0 Fluid Retention Fluid Retention includes (by COSTART): edema (peripheral, localized, generalized, lymphedema, pulmonary edema, and edema otherwise not specified) and effusion (pleural, pericardial, and ascites); no premedication given with the 60 mg/m 2 dose Regardless of Premedication Any 56 61 13 Severe 8 17 0 Neurosensory Any 57 50 20 Severe 6 0 0 Myalgia 23 33 3 Cutaneous Any 45 61 31 Severe 5 17 0 Asthenia Any 65 44 66 Severe 17 22 0 Diarrhea Any 42 28 NA Severe 6 11 Stomatitis Any 53 67 19 Severe 8 39 1 In the three-arm monotherapy trial, TAX313, which compared docetaxel 60 mg/m 2, 75 mg/m 2 and 100 mg/m 2 in advanced breast cancer, grade 3/4 or severe adverse reactions occurred in 49.0% of patients treated with docetaxel 60 mg/m 2 compared to 55.3% and 65.9% treated with 75 mg/m 2 and 100 mg/m 2, respectively.
Discontinuation due to adverse reactions was reported in 5.3% of patients treated with 60 mg/m 2 versus 6.9% and 16.5% for patients treated at 75 and 100 mg/m 2, respectively. Deaths within 30 days of last treatment occurred in 4.0% of patients treated with 60 mg/m 2 compared to 5.3% and 1.6% for patients treated at 75 mg/m 2 and 100 mg/m 2, respectively.
The following adverse reactions were associated with increasing docetaxel doses: fluid retention (26%, 38%, and 46% at 60 mg/m 2, 75 mg/m 2, and 100 mg/m 2, respectively), thrombocytopenia (7%, 11% and 12%, respectively), neutropenia (92%, 94%, and 97%, respectively), febrile neutropenia (5%, 7%, and 14%, respectively), treatment-related grade 3/4 infection (2%, 3%, and 7%, respectively) and anemia (87%, 94%, and 97%, respectively). Combination therapy with docetaxel in the adjuvant treatment of breast cancer The following table presents treatment-emergent adverse reactions observed in 744 patients, who were treated with docetaxel 75 mg/m 2 every 3 weeks in combination with doxorubicin and cyclophosphamide (see Table 6).
Table 6: Clinically Important Treatment-Emergent Adverse Reactions Regardless of Causal Relationship in Patients Receiving Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAX316) Docetaxel 75 mg/m 2 + Doxorubicin 50 mg/m 2 + Cyclophosphamide 500 mg/m 2 (TAC) n=744 % Fluorouracil 500 mg/m 2 + Doxorubicin 50 mg/m 2 + Cyclophosphamide 500 mg/m 2 (FAC) n=736 % Adverse Reaction Any Grade 3/4 Any Grade 3/4 Anemia 92 4 72 2 Neutropenia 71 66 82 49 Fever in absence of infection 47 1 17 0 Infection 39 4 36 2 Thrombocytopenia 39 2 28 1 Febrile neutropenia 25 N/A 3 N/A Neutropenic infection 12 N/A 6 N/A Hypersensitivity reactions 13 1 4 0 Lymphedema 4 0 1 0 Fluid Retention COSTART term and grading system for events related to treatment. 35 1 15 0 Peripheral edema 27 0 7 0 Weight gain 13 0 9 0 Neuropathy sensory 26 0 10 0 Neuro-cortical 5 1 6 1 Neuropathy motor 4 0 2 0 Neuro-cerebellar 2 0 2 0 Syncope 2 1 1 0 Alopecia 98 N/A 97 N/A Skin toxicity 27 1 18 0 Nail disorders 19 0 14 0 Nausea 81 5 88 10 Stomatitis 69 7 53 2 Vomiting 45 4 59 7 Diarrhea 35 4 28 2 Constipation 34 1 32 1 Taste perversion 28 1 15 0 Anorexia 22 2 18 1 Abdominal Pain 11 1 5 0 Amenorrhea 62 N/A 52 N/A Cough 14 0 10 0 Cardiac dysrhythmias 8 0 6 0 Vasodilatation 27 1 21 1 Hypotension 2 0 1 0 Phlebitis 1 0 1 0 Asthenia 81 11 71 6 Myalgia 27 1 10 0 Arthralgia 19 1 9 0 Lacrimation disorder 11 0 7 0 Conjunctivitis 5 0 7 0 Of the 744 patients treated with TAC, 36.3% experienced severe treatment-emergent adverse reactions compared to 26.6% of the 736 patients treated with FAC. Dose reductions due to hematologic toxicity occurred in 1% of cycles in the TAC arm versus 0.1% of cycles in the FAC arm.
Six percent of patients treated with TAC discontinued treatment due to adverse reactions, compared to 1.1% treated with FAC; fever in the absence of infection and allergy being the most common reasons for withdrawal among TAC-treated patients. Two patients died in each arm within 30 days of their last study treatment; 1 death per arm was attributed to study drugs.
Fever and infection During the treatment period, fever in the absence of infection was seen in 46.5% of TAC-treated patients and in 17.1% of FAC-treated patients. Grade 3/4 fever in the absence of infection was seen in 1.3% and 0% of TAC and FAC-treated patients, respectively. Infection was seen in 39.4% of TAC-treated patients compared to 36.3% of FAC-treated patients.
Grade 3/4 infection was seen in 3.9% and 2.2% of TAC-treated and FAC-treated patients, respectively. There were no septic deaths in either treatment arm during the treatment period. Gastrointestinal reactions In addition to gastrointestinal reactions reflected in the table above, 7 patients in the TAC arm were reported to have colitis/enteritis/large intestine perforation versus one patient in the FAC arm.
Five of the 7 TAC-treated patients required treatment discontinuation; no deaths due to these events occurred during the treatment period. Cardiovascular reactions More cardiovascular reactions were reported in the TAC arm versus the FAC arm during the treatment period: arrhythmias, all grades (6.2% vs 4.9%), and hypotension, all grades (1.9% vs 0.8%).
Twenty-six (26) patients (3.5%) in the TAC arm and 17 patients (2.3%) in the FAC arm developed CHF during the study period. All except one patient in each arm were diagnosed with CHF during the follow-up period. Two (2) patients in TAC arm and 4 patients in FAC arm died due to CHF. The risk of CHF was higher in the TAC arm in the first year, and then was similar in both treatment arms.
Adverse reactions during the follow-up period (median follow-up time of 8 years) In study TAX316, the most common adverse reactions that started during the treatment period and persisted into the follow-up period in TAC and FAC patients are described below (median follow-up time of 8 years). Nervous system disorders In study TAX316, peripheral sensory neuropathy started during the treatment period and persisted into the follow-up period in 84 patients (11.3%) in TAC arm and 15 patients (2%) in FAC arm.
At the end of the follow-up period (median follow-up time of 8 years), peripheral sensory neuropathy was observed to be ongoing in 10 patients (1.3%) in TAC arm, and in 2 patients (0.3%) in FAC arm. Skin and subcutaneous tissue disorders In study TAX316, alopecia persisting into the follow-up period after the end of chemotherapy was reported in 687 of 744 TAC patients (92.3%) and 645 of 736 FAC patients (87.6%).
At the end of the follow-up period (actual median follow-up time of 8 years), alopecia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2.2%). Reproductive system and breast disorders In study TAX316, amenorrhea that started during the treatment period and persisted into the follow-up period after the end of chemotherapy was reported in 202 of 744 TAC patients (27.2%) and 125 of 736 FAC patients (17.0%).
Amenorrhea was observed to be ongoing at the end of the follow-up period (median follow-up time of 8 years) in 121 of 744 TAC patients (16.3%) and 86 FAC patients (11.7%). General disorders and administration site conditions In study TAX316, peripheral edema that started during the treatment period and persisted into the follow-up period after the end of chemotherapy was observed in 119 of 744 TAC patients (16.0%) and 23 of 736 FAC patients (3.1%).
At the end of the follow-up period (actual median follow-up time of 8 years), peripheral edema was ongoing in 19 TAC patients (2.6%) and 4 FAC patients (0.5%). In study TAX316, lymphedema that started during the treatment period and persisted into the follow-up period after the end of chemotherapy was reported in 11 of 744 TAC patients (1.5%) and 1 of 736 FAC patients (0.1%).
At the end of the follow-up period (actual median follow-up time of 8 years), lymphedema was observed to be ongoing in 6 TAC patients (0.8%) and 1 FAC patient (0.1%). In study TAX316, asthenia that started during the treatment period and persisted into the follow-up period after the end of chemotherapy was reported in 236 of 744 TAC patients (31.7%) and 180 of 736 FAC patients (24.5%).
At the end of the follow-up period (actual median follow-up time of 8 years), asthenia was observed to be ongoing in 29 TAC patients (3.9%) and 16 FAC patients (2.2%). Acute myeloid leukemia (AML)/Myelodysplastic syndrome (MDS) AML occurred in the adjuvant breast cancer trial (TAX316). The cumulative risk of developing treatment-related AML at median follow-up time of 8 years in TAX316 was 0.4% for TAC-treated patients and 0.1% for FAC-treated patients.
One TAC patient (0.1%) and 1 FAC patient (0.1%) died due to AML during the follow-up period (median follow-up time of 8 years). Myelodysplastic syndrome occurred in 2 of 744 (0.3%) patients who received TAC and in 1 of 736 (0.1%) patients who received FAC. AML occurs at a higher frequency when these agents are given in combination with radiation therapy.
Lung Cancer Monotherapy with docetaxel for unresectable, locally advanced or metastatic NSCLC previously treated with platinum-based chemotherapy Docetaxel 75 mg/m 2: Treatment-emergent adverse drug reactions are shown in Table 7. Included in this table are safety data for a total of 176 patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who were treated in two randomized, controlled trials.
These reactions were described using NCI Common Toxicity Criteria regardless of relationship to study treatment, except for the hematologic toxicities or where otherwise noted. Table 7: Treatment-Emergent Adverse Reactions Regardless of Relationship to Treatment in Patients Receiving Docetaxel as Monotherapy for Non-small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN Adverse Reaction Docetaxel 75 mg/m 2 n=176 % Best Supportive Care n=49 % Vinorelbine/Ifosfamide n=119 % Neutropenia Any 84 14 83 Grade 3/4 65 12 57 Leukopenia Any 84 6 89 Grade 3/4 49 0 43 Thrombocytopenia Any 8 0 8 Grade 3/4 3 0 2 Anemia Any 91 55 91 Grade 3/4 9 12 14 Febrile Neutropenia Febrile Neutropenia: ANC grade 4 with fever >38°C with intravenous antibiotics and/or hospitalization 6 NA Not Applicable 1 Infection Any 34 29 30 Grade 3/4 10 6 9 Treatment Related Mortality 3 NA 3 Hypersensitivity Reactions Any 6 0 1 Grade 3/4 3 0 0 Fluid Retention Any 34 ND Not Done 23 Severe 3 3 Neurosensory Any 23 14 29 Grade 3/4 2 6 5 Neuromotor Any 16 8 10 Grade 3/4 5 6 3 Skin Any 20 6 17 Grade 3/4 1 2 1 Gastrointestinal Nausea Any 34 31 31 Grade 3/4 5 4 8 Vomiting Any 22 27 22 Grade 3/4 3 2 6 Diarrhea Any 23 6 12 Grade 3/4 3 0 4 Alopecia 56 35 50 Asthenia Any 53 57 54 Severe COSTART term and grading system 18 39 23 Stomatitis Any 26 6 8 Grade 3/4 2 0 1 Pulmonary Any 41 49 45 Grade 3/4 21 29 19 Nail Disorder Any 11 0 2 Severe 1 0 0 Myalgia Any 6 0 3 Severe 0 0 0 Arthralgia Any 3 2 2 Severe 0 0 1 Taste Perversion Any 6 0 0 Severe 1 0 0 Combination therapy with docetaxel in chemotherapy-naive advanced unresectable or metastatic NSCLC Table 8 presents safety data from two arms of an open label, randomized controlled trial (TAX326) that enrolled patients with unresectable stage IIIB or IV non-small cell lung cancer and no history of prior chemotherapy.
Adverse reactions were described using the NCI Common Toxicity Criteria except where otherwise noted. Table 8: Adverse Reactions Regardless of Relationship to Treatment in Chemotherapy-Naive Advanced Non-small Cell Lung Cancer Patients Receiving Docetaxel in Combination with Cisplatin Adverse Reaction Docetaxel 75 mg/m 2 + Cisplatin 75 mg/m 2 n=406 % Vinorelbine 25 mg/m 2 + Cisplatin 100 mg/m 2 n=396 % Neutropenia Any 91 90 Grade 3/4 74 78 Febrile Neutropenia 5 5 Thrombocytopenia Any 15 15 Grade 3/4 3 4 Anemia Any 89 94 Grade 3/4 7 25 Infection Any 35 37 Grade 3/4 8 8 Fever in absence of infection Any 33 29 Grade 3/4 <1 1 Hypersensitivity Reaction Replaces NCI term "Allergy" Any 12 4 Grade 3/4 3 <1 Fluid Retention COSTART term and grading system Any 54 42 All severe or life-threatening events 2 2 Pleural effusion Any 23 22 All severe or life-threatening events 2 2 Peripheral edema Any 34 18 All severe or life-threatening events <1 <1 Weight gain Any 15 9 All severe or life-threatening events <1 <1 Neurosensory Any 47 42 Grade 3/4 4 4 Neuromotor Any 19 17 Grade 3/4 3 6 Skin Any 16 14 Grade 3/4 <1 1 Nausea Any 72 76 Grade 3/4 10 17 Vomiting Any 55 61 Grade 3/4 8 16 Diarrhea Any 47 25 Grade 3/4 7 3 Anorexia Any 42 40 All severe or life-threatening events 5 5 Stomatitis Any 24 21 Grade 3/4 2 1 Alopecia Any 75 42 Grade 3 <1 0 Asthenia Any 74 75 All severe or life-threatening events 12 14 Nail Disorder Any 14 <1 All severe events <1 0 Myalgia Any 18 12 All severe events <1 <1 Deaths within 30 days of last study treatment occurred in 31 patients (7.6%) in the docetaxel+cisplatin arm and 37 patients (9.3%) in the vinorelbine+cisplatin arm.
Deaths within 30 days of last study treatment attributed to study drug occurred in 9 patients (2.2%) in the docetaxel+cisplatin arm and 8 patients (2.0%) in the vinorelbine+cisplatin arm. The second comparison in the study, vinorelbine+cisplatin versus docetaxel+carboplatin (which did not demonstrate a superior survival associated with docetaxel [see Clinical Studies (14.3)]) demonstrated a higher incidence of thrombocytopenia, diarrhea, fluid retention, hypersensitivity reactions, skin toxicity, alopecia and nail changes on the docetaxel+carboplatin arm, while a higher incidence of anemia, neurosensory toxicity, nausea, vomiting, anorexia and asthenia was observed on the vinorelbine+cisplatin arm.
Prostate Cancer Combination therapy with docetaxel in patients with prostate cancer The following data are based on the experience of 332 patients, who were treated with docetaxel 75 mg/m 2 every 3 weeks in combination with prednisone 5 mg orally twice daily (see Table 9). Table 9: Clinically Important Treatment-Emergent Adverse Reactions (Regardless of Relationship) in Patients with Prostate Cancer Who Received Docetaxel in Combination with Prednisone (TAX327) Docetaxel 75 mg/m 2 every 3 weeks + prednisone 5 mg twice daily n=332 % Mitoxantrone 12 mg/m 2 every 3 weeks + prednisone 5 mg twice daily n=335 % Adverse Reaction Any Grade 3/4 Any Grade 3/4 Anemia 67 5 58 2 Neutropenia 41 32 48 22 Thrombocytopenia 3 1 8 1 Febrile neutropenia 3 N/A 2 N/A Infection 32 6 20 4 Epistaxis 6 0 2 0 Allergic Reactions 8 1 1 0 Fluid Retention Related to treatment 24 1 5 0 Weight Gain 8 0 3 0 Peripheral Edema 18 0 2 0 Neuropathy Sensory 30 2 7 0 Neuropathy Motor 7 2 3 1 Rash/Desquamation 6 0 3 1 Alopecia 65 N/A 13 N/A Nail Changes 30 0 8 0 Nausea 41 3 36 2 Diarrhea 32 2 10 1 Stomatitis/Pharyngitis 20 1 8 0 Taste Disturbance 18 0 7 0 Vomiting 17 2 14 2 Anorexia 17 1 14 0 Cough 12 0 8 0 Dyspnea 15 3 9 1 Cardiac left ventricular function 10 0 22 1 Fatigue 53 5 35 5 Myalgia 15 0 13 1 Tearing 10 1 2 0 Arthralgia 8 1 5 1 Gastric Cancer Combination therapy with docetaxel in gastric adenocarcinoma Data in the following table are based on the experience of 221 patients with advanced gastric adenocarcinoma and no history of prior chemotherapy for advanced disease who were treated with docetaxel 75 mg/m 2 in combination with cisplatin and fluorouracil (see Table 10).
Table 10: Clinically Important Treatment-Emergent Adverse Reactions Regardless of Relationship to Treatment in the Gastric Cancer Study Docetaxel 75 mg/m 2 + cisplatin 75 mg/m 2 + fluorouracil 750 mg/m 2 n=221 Cisplatin 100 mg/m 2 + fluorouracil 1000 mg/m 2 n=224 Adverse Reaction Any % Grade 3/4 % Any % Grade 3/4 % Clinically important treatment-emergent adverse reactions were determined based upon frequency, severity, and clinical impact of the adverse reaction. Anemia 97 18 93 26 Neutropenia 96 82 83 57 Fever in the absence of infection 36 2 23 1 Thrombocytopenia 26 8 39 14 Infection 29 16 23 10 Febrile neutropenia 16 N/A 5 N/A Neutropenic infection 16 N/A 10 N/A Allergic reactions 10 2 6 0 Fluid retention Related to treatment 15 0 4 0 Edema 13 0 3 0 Lethargy 63 21 58 18 Neurosensory 38 8 25 3 Neuromotor 9 3 8 3 Dizziness 16 5 8 2 Alopecia 67 5 41 1 Rash/itch 12 1 9 0 Nail changes 8 0 0 0 Skin desquamation 2 0 0 0 Nausea 73 16 76 19 Vomiting 67 15 73 19 Anorexia 51 13 54 12 Stomatitis 59 21 61 27 Diarrhea 78 20 50 8 Constipation 25 2 34 3 Esophagitis/dysphagia/odynophagia 16 2 14 5 Gastrointestinal pain/cramping 11 2 7 3 Cardiac dysrhythmias 5 2 2 1 Myocardial ischemia 1 0 3 2 Tearing 8 0 2 0 Altered hearing 6 0 13 2 Head and Neck Cancer Combination therapy with docetaxel in head and neck cancer Table 11 summarizes the safety data obtained from patients that received induction chemotherapy with docetaxel 75 mg/m 2 in combination with cisplatin and fluorouracil followed by radiotherapy (TAX323; 174 patients) or chemoradiotherapy (TAX324; 251 patients).
The treatment regimens are described in Section 14.6. Table 11: Clinically Important Treatment-Emergent Adverse Reactions (Regardless of Relationship) in Patients with SCCHN Receiving Induction Chemotherapy with Docetaxel in Combination with Cisplatin and Fluorouracil Followed by Radiotherapy (TAX323) or Chemoradiotherapy (TAX324) TAX323 (n=355) TAX324 (n=494) Docetaxel arm (n=174) Comparator arm (n=181) Docetaxel arm (n=251) Comparator arm (n=243) Adverse Reaction (by Body System) Any % Grade 3/4 % Any % Grade 3/4 % Any % Grade 3/4 % Any % Grade 3/4 % Clinically important treatment-emergent adverse reactions based upon frequency, severity, and clinical impact.
Neutropenia 93 76 87 53 95 84 84 56 Anemia 89 9 88 14 90 12 86 10 Thrombocytopenia 24 5 47 18 28 4 31 11 Infection 27 9 26 8 23 6 28 5 Febrile neutropenia Febrile neutropenia: grade ≥2 fever concomitant with grade 4 neutropenia requiring intravenous antibiotics and/or hospitalization. 5 N/A 2 N/A 12 N/A 7 N/A Neutropenic infection 14 N/A 8 N/A 12 N/A 8 N/A Cancer pain 21 5 16 3 17 9 20 11 Lethargy 41 3 38 3 61 5 56 10 Fever in the absence of infection 32 1 37 0 30 4 28 3 Myalgia 10 1 7 0 7 0 7 2 Weight loss 21 1 27 1 14 2 14 2 Allergy 6 0 3 0 2 0 0 0 Fluid retention Related to treatment. Edema only Weight gain only 20 13 6 0 0 0 14 7 6 1 0 0 13 12 0 1 1 0 7 6 1 2 1 0 Dizziness 2 0 5 1 16 4 15 2 Neurosensory 18 1 11 1 14 1 14 0 Altered hearing 6 0 10 3 13 1 19 3 Neuromotor 2 1 4 1 9 0 10 2 Alopecia 81 11 43 0 68 4 44 1 Rash/itch 12 0 6 0 20 0 16 1 Dry skin 6 0 2 0 5 0 3 0 Desquamation 4 1 6 0 2 0 5 0 Nausea 47 1 51 7 77 14 80 14 Stomatitis 43 4 47 11 66 21 68 27 Vomiting 26 1 39 5 56 8 63 10 Diarrhea 33 3 24 4 48 7 40 3 Constipation 17 1 16 1 27 1 38 1 Anorexia 16 1 25 3 40 12 34 12 Esophagitis/dysphagia/ Odynophagia 13 1 18 3 25 13 26 10 Taste, sense of smell altered 10 0 5 0 20 0 17 1 Gastrointestinal pain/cramping 8 1 9 1 15 5 10 2 Heartburn 6 0 6 0 13 2 13 1 Gastrointestinal bleeding 4 2 0 0 5 1 2 1 Cardiac dysrhythmia 2 2 2 1 6 3 5 3 Venous Includes superficial and deep vein thrombosis and pulmonary embolism 3 2 6 2 4 2 5 4 Ischemia myocardial 2 2 1 0 2 1 1 1 Tearing 2 0 1 0 2 0 2 0 Conjunctivitis 1 0 1 0 1 0 0.4 0
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified from clinical trials and/or postmarketing surveillance. Because these reactions are reported from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Body as a whole: diffuse pain, chest pain, radiation recall phenomenon, injection site recall reaction (recurrence of skin reaction at a site of previous extravasation following administration of docetaxel at a different site) at the site of previous extravasation. Cardiovascular: atrial fibrillation, deep vein thrombosis, ECG abnormalities, thrombophlebitis, pulmonary embolism, syncope, tachycardia, myocardial infarction.
Ventricular arrhythmia including ventricular tachycardia, in patients treated with docetaxel in combination regimens including doxorubicin, 5-fluorouracil and/or cyclophosphamide may be associated with fatal outcome. Cutaneous: cutaneous lupus erythematosus, bullous eruptions such as erythema multiforme and severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome, toxic epidermal necrolysis and acute generalized exanthematous pustulosis, scleroderma-like changes (usually preceded by peripheral lymphedema), severe palmar-plantar erythrodysesthesia, and permanent alopecia.
Gastrointestinal: enterocolitis, including colitis, ischemic colitis, and neutropenic enterocolitis, which may be fatal. Abdominal pain, anorexia, constipation, duodenal ulcer, esophagitis, gastrointestinal hemorrhage, gastrointestinal perforation, intestinal obstruction, ileus, and dehydration as a consequence of gastrointestinal events.
Hearing: ototoxicity, hearing disorders and/or hearing loss, including during use with other ototoxic drugs. Hematologic: bleeding episodes, disseminated intravascular coagulation (DIC), often in association with sepsis or multiorgan failure. Hepatic: hepatitis, sometimes fatal, primarily in patients with pre-existing liver disorders.
Hypersensitivity: anaphylactic shock with fatal outcome in patients who received premedication. Severe hypersensitivity reactions with fatal outcome with docetaxel in patients who previously experienced hypersensitivity reactions to paclitaxel. Metabolism and nutrition disorders: electrolyte imbalance, including hyponatremia, hypokalemia, hypomagnesemia, and hypocalcemia.
Tumor lysis syndrome, sometimes fatal. Neurologic: confusion, seizures or transient loss of consciousness, sometimes appearing during the infusion of the drug. Ophthalmologic: conjunctivitis, lacrimation or lacrimation with or without conjunctivitis, cystoid macular edema (CME). Excessive tearing which may be attributable to lacrimal duct obstruction.
Transient visual disturbances (flashes, flashing lights, scotomata), typically occurring during drug infusion and reversible upon discontinuation of the infusion, in association with hypersensitivity reactions. Respiratory: dyspnea, acute pulmonary edema, acute respiratory distress syndrome/pneumonitis, interstitial lung disease, interstitial pneumonia, respiratory failure, and pulmonary fibrosis, which may be fatal.
Radiation pneumonitis in patients receiving concomitant radiotherapy. Renal: renal insufficiency and renal failure, the majority of cases were associated with concomitant nephrotoxic drugs. Second primary malignancies: second primary malignancies, including AML, MDS, NHL, and renal cancer [see Warnings and Precautions (5.7)].
Musculoskeletal disorder: myositis.
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reaction | All Tumor Types Normal LFTs Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN n=2045 % | All Tumor Types Elevated LFTs Elevated Baseline LFTs: AST and/or ALT >1.5 times ULN concurrent with alkaline phosphatase >2.5 times ULN n=61 % | Breast Cancer Normal LFTs n=965 % |
|---|---|---|---|
| Hematologic | |||
| Neutropenia | |||
| <2000 cells/mm 3 | 96 | 96 | 99 |
| <500 cells/mm 3 | 75 | 88 | 86 |
| Leukopenia | |||
| <4000 cells/mm 3 | 96 | 98 | 99 |
| <1000 cells/mm 3 | 32 | 47 | 44 |
| Thrombocytopenia | |||
| <100,000 cells/mm 3 | 8 | 25 | 9 |
| Anemia | |||
| <11 g/dL | 90 | 92 | 94 |
| <8 g/dL | 9 | 31 | 8 |
| Febrile Neutropenia Febrile Neutropenia: ANC grade 4 with fever >38°C with intravenous antibiotics and/or hospitalization | 11 | 26 | 12 |
| Septic Death | 2 | 5 | 1 |
| Non-Septic Death | 1 | 7 | 1 |
| Infections | |||
| Any | 22 | 33 | 22 |
| Severe | 6 | 16 | 6 |
| Fever in Absence of Infection | |||
| Any | 31 | 41 | 35 |
| Severe | 2 | 8 | 2 |
| Hypersensitivity Reactions | |||
| Regardless of Premedication | |||
| Any | 21 | 20 | 18 |
| Severe | 4 | 10 | 3 |
| With 3-day Premedication | n=92 | n=3 | n=92 |
| Any | 15 | 33 | 15 |
| Severe | 2 | 0 | 2 |
| Fluid Retention | |||
| Regardless of Premedication | |||
| Any | 47 | 39 | 60 |
| Severe | 7 | 8 | 9 |
| With 3-day Premedication | n=92 | n=3 | n=92 |
| Any | 64 | 67 | 64 |
| Severe | 7 | 33 | 7 |
| Neurosensory | |||
| Any | 49 | 34 | 58 |
| Severe | 4 | 0 | 6 |
| Cutaneous | |||
| Any | 48 | 54 | 47 |
| Severe | 5 | 10 | 5 |
| Nail Changes | |||
| Any | 31 | 23 | 41 |
| Severe | 3 | 5 | 4 |
| Gastrointestinal | |||
| Nausea | 39 | 38 | 42 |
| Vomiting | 22 | 23 | 23 |
| Diarrhea | 39 | 33 | 43 |
| Severe | 5 | 5 | 6 |
| Stomatitis | |||
| Any | 42 | 49 | 52 |
| Severe | 6 | 13 | 7 |
| Alopecia | 76 | 62 | 74 |
| Asthenia | |||
| Any | 62 | 53 | 66 |
| Severe | 13 | 25 | 15 |
| Myalgia | |||
| Any | 19 | 16 | 21 |
| Severe | 2 | 2 | 2 |
| Arthralgia | 9 | 7 | 8 |
| Infusion Site Reactions | 4 | 3 | 4 |
| Docetaxel 100 mg/m 2 | Docetaxel 60 mg/m 2 | |||
|---|---|---|---|---|
| Adverse Reaction | Normal LFTs Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN n=730 % | Elevated LFTs Elevated Baseline LFTs: AST and/or ALT >1.5 times ULN concurrent with alkaline phosphatase >2.5 times ULN n=18 % | Normal LFTs n=174 % | |
| Neutropenia | ||||
| Any | <2000 cells/mm 3 | 98 | 100 | 95 |
| Grade 4 | <500 cells/mm 3 | 84 | 94 | 75 |
| Thrombocytopenia | ||||
| Any | <100,000 cells/mm 3 | 11 | 44 | 14 |
| Grade 4 | <20,000 cells/mm 3 | 1 | 17 | 1 |
| Anemia | <11 g/dL | 95 | 94 | 65 |
| InfectionIncidence of infection requiring hospitalization and/or intravenous antibiotics was 8.5% (n=62) among the 730 patients with normal LFTs at baseline; 7 patients had concurrent grade 3 neutropenia, and 46 patients had grade 4 neutropenia. | ||||
| Any | 23 | 39 | 1 | |
| Grade 3 and 4 | 7 | 33 | 0 | |
| Febrile NeutropeniaFebrile Neutropenia: For 100 mg/m 2, ANC grade 4 and fever >38°C with intravenous antibiotics and/or hospitalization; for 60 mg/m 2, ANC grade 3/4 and fever >38.1°C | ||||
| By Patient | 12 | 33 | 0 | |
| By Course | 2 | 9 | 0 | |
| Septic Death | 2 | 6 | 1 | |
| Non-Septic Death | 1 | 11 | 0 | |
| Docetaxel 100 mg/m 2 | Docetaxel 60 mg/m 2 | ||
|---|---|---|---|
| Adverse Reaction | Normal LFTs Normal Baseline LFTs: Transaminases ≤1.5 times ULN or alkaline phosphatase ≤2.5 times ULN or isolated elevations of transaminases or alkaline phosphatase up to 5 times ULN n=730 % | Elevated LFTs Elevated Baseline Liver Function: AST and/or ALT >1.5 times ULN concurrent with alkaline phosphatase >2.5 times ULN n=18 % | Normal LFTs n=174 % |
| NA = not available | |||
| Acute Hypersensitivity | |||
| Reaction Regardless of Premedication | |||
| Any | 13 | 6 | 1 |
| Severe | 1 | 0 | 0 |
| Fluid RetentionFluid Retention includes (by COSTART): edema (peripheral, localized, generalized, lymphedema, pulmonary edema, and edema otherwise not specified) and effusion (pleural, pericardial, and ascites); no premedication given with the 60 mg/m 2 dose | |||
| Regardless of Premedication | |||
| Any | 56 | 61 | 13 |
| Severe | 8 | 17 | 0 |
| Neurosensory | |||
| Any | 57 | 50 | 20 |
| Severe | 6 | 0 | 0 |
| Myalgia | 23 | 33 | 3 |
| Cutaneous | |||
| Any | 45 | 61 | 31 |
| Severe | 5 | 17 | 0 |
| Asthenia | |||
| Any | 65 | 44 | 66 |
| Severe | 17 | 22 | 0 |
| Diarrhea | |||
| Any | 42 | 28 | NA |
| Severe | 6 | 11 | |
| Stomatitis | |||
| Any | 53 | 67 | 19 |
| Severe | 8 | 39 | 1 |
| Docetaxel 75 mg/m 2+ Doxorubicin 50 mg/m 2+ Cyclophosphamide 500 mg/m 2(TAC) n=744 % | Fluorouracil 500 mg/m 2+ Doxorubicin 50 mg/m 2+ Cyclophosphamide 500 mg/m 2(FAC) n=736 % | |||
|---|---|---|---|---|
| Adverse Reaction | Any | Grade 3/4 | Any | Grade 3/4 |
| Anemia | 92 | 4 | 72 | 2 |
| Neutropenia | 71 | 66 | 82 | 49 |
| Fever in absence of infection | 47 | 1 | 17 | 0 |
| Infection | 39 | 4 | 36 | 2 |
| Thrombocytopenia | 39 | 2 | 28 | 1 |
| Febrile neutropenia | 25 | N/A | 3 | N/A |
| Neutropenic infection | 12 | N/A | 6 | N/A |
| Hypersensitivity reactions | 13 | 1 | 4 | 0 |
| Lymphedema | 4 | 0 | 1 | 0 |
| Fluid RetentionCOSTART term and grading system for events related to treatment. | 35 | 1 | 15 | 0 |
| Peripheral edema | 27 | 0 | 7 | 0 |
| Weight gain | 13 | 0 | 9 | 0 |
| Neuropathy sensory | 26 | 0 | 10 | 0 |
| Neuro-cortical | 5 | 1 | 6 | 1 |
| Neuropathy motor | 4 | 0 | 2 | 0 |
| Neuro-cerebellar | 2 | 0 | 2 | 0 |
| Syncope | 2 | 1 | 1 | 0 |
| Alopecia | 98 | N/A | 97 | N/A |
| Skin toxicity | 27 | 1 | 18 | 0 |
| Nail disorders | 19 | 0 | 14 | 0 |
| Nausea | 81 | 5 | 88 | 10 |
| Stomatitis | 69 | 7 | 53 | 2 |
| Vomiting | 45 | 4 | 59 | 7 |
| Diarrhea | 35 | 4 | 28 | 2 |
| Constipation | 34 | 1 | 32 | 1 |
| Taste perversion | 28 | 1 | 15 | 0 |
| Anorexia | 22 | 2 | 18 | 1 |
| Abdominal Pain | 11 | 1 | 5 | 0 |
| Amenorrhea | 62 | N/A | 52 | N/A |
| Cough | 14 | 0 | 10 | 0 |
| Cardiac dysrhythmias | 8 | 0 | 6 | 0 |
| Vasodilatation | 27 | 1 | 21 | 1 |
| Hypotension | 2 | 0 | 1 | 0 |
| Phlebitis | 1 | 0 | 1 | 0 |
| Asthenia | 81 | 11 | 71 | 6 |
| Myalgia | 27 | 1 | 10 | 0 |
| Arthralgia | 19 | 1 | 9 | 0 |
| Lacrimation disorder | 11 | 0 | 7 | 0 |
| Conjunctivitis | 5 | 0 | 7 | 0 |
| Adverse Reaction | Docetaxel 75 mg/m 2 n=176 % | Best Supportive Care n=49 % | Vinorelbine/Ifosfamide n=119 % |
|---|---|---|---|
| Neutropenia | |||
| Any | 84 | 14 | 83 |
| Grade 3/4 | 65 | 12 | 57 |
| Leukopenia | |||
| Any | 84 | 6 | 89 |
| Grade 3/4 | 49 | 0 | 43 |
| Thrombocytopenia | |||
| Any | 8 | 0 | 8 |
| Grade 3/4 | 3 | 0 | 2 |
| Anemia | |||
| Any | 91 | 55 | 91 |
| Grade 3/4 | 9 | 12 | 14 |
| Febrile | |||
| NeutropeniaFebrile Neutropenia: ANC grade 4 with fever >38°C with intravenous antibiotics and/or hospitalization | 6 | NA Not Applicable | 1 |
| Infection | |||
| Any | 34 | 29 | 30 |
| Grade 3/4 | 10 | 6 | 9 |
| Treatment Related Mortality | 3 | NA | 3 |
| Hypersensitivity Reactions | |||
| Any | 6 | 0 | 1 |
| Grade 3/4 | 3 | 0 | 0 |
| Fluid Retention | |||
| Any | 34 | ND Not Done | 23 |
| Severe | 3 | 3 | |
| Neurosensory | |||
| Any | 23 | 14 | 29 |
| Grade 3/4 | 2 | 6 | 5 |
| Neuromotor | |||
| Any | 16 | 8 | 10 |
| Grade 3/4 | 5 | 6 | 3 |
| Skin | |||
| Any | 20 | 6 | 17 |
| Grade 3/4 | 1 | 2 | 1 |
| Gastrointestinal | |||
| Nausea | |||
| Any | 34 | 31 | 31 |
| Grade 3/4 | 5 | 4 | 8 |
| Vomiting | |||
| Any | 22 | 27 | 22 |
| Grade 3/4 | 3 | 2 | 6 |
| Diarrhea | |||
| Any | 23 | 6 | 12 |
| Grade 3/4 | 3 | 0 | 4 |
| Alopecia | 56 | 35 | 50 |
| Asthenia | |||
| Any | 53 | 57 | 54 |
| Severe COSTART term and grading system | 18 | 39 | 23 |
| Stomatitis | |||
| Any | 26 | 6 | 8 |
| Grade 3/4 | 2 | 0 | 1 |
| Pulmonary | |||
| Any | 41 | 49 | 45 |
| Grade 3/4 | 21 | 29 | 19 |
| Nail Disorder | |||
| Any | 11 | 0 | 2 |
| Severe | 1 | 0 | 0 |
| Myalgia | |||
| Any | 6 | 0 | 3 |
| Severe | 0 | 0 | 0 |
| Arthralgia | |||
| Any | 3 | 2 | 2 |
| Severe | 0 | 0 | 1 |
| Taste Perversion | |||
| Any | 6 | 0 | 0 |
| Severe | 1 | 0 | 0 |
| Adverse Reaction | Docetaxel 75 mg/m 2+ Cisplatin 75 mg/m 2 n=406 % | Vinorelbine 25 mg/m 2+ Cisplatin 100 mg/m 2 n=396 % |
|---|---|---|
| Neutropenia | ||
| Any | 91 | 90 |
| Grade 3/4 | 74 | 78 |
| Febrile Neutropenia | 5 | 5 |
| Thrombocytopenia | ||
| Any | 15 | 15 |
| Grade 3/4 | 3 | 4 |
| Anemia | ||
| Any | 89 | 94 |
| Grade 3/4 | 7 | 25 |
| Infection | ||
| Any | 35 | 37 |
| Grade 3/4 | 8 | 8 |
| Fever in absence of infection | ||
| Any | 33 | 29 |
| Grade 3/4 | <1 | 1 |
| Hypersensitivity Reaction Replaces NCI term "Allergy" | ||
| Any | 12 | 4 |
| Grade 3/4 | 3 | <1 |
| Fluid RetentionCOSTART term and grading system | ||
| Any | 54 | 42 |
| All severe or life-threatening events | 2 | 2 |
| Pleural effusion | ||
| Any | 23 | 22 |
| All severe or life-threatening events | 2 | 2 |
| Peripheral edema | ||
| Any | 34 | 18 |
| All severe or life-threatening events | <1 | <1 |
| Weight gain | ||
| Any | 15 | 9 |
| All severe or life-threatening events | <1 | <1 |
| Neurosensory | ||
| Any | 47 | 42 |
| Grade 3/4 | 4 | 4 |
| Neuromotor | ||
| Any | 19 | 17 |
| Grade 3/4 | 3 | 6 |
| Skin | ||
| Any | 16 | 14 |
| Grade 3/4 | <1 | 1 |
| Nausea | ||
| Any | 72 | 76 |
| Grade 3/4 | 10 | 17 |
| Vomiting | ||
| Any | 55 | 61 |
| Grade 3/4 | 8 | 16 |
| Diarrhea | ||
| Any | 47 | 25 |
| Grade 3/4 | 7 | 3 |
| Anorexia | ||
| Any | 42 | 40 |
| All severe or life-threatening events | 5 | 5 |
| Stomatitis | ||
| Any | 24 | 21 |
| Grade 3/4 | 2 | 1 |
| Alopecia | ||
| Any | 75 | 42 |
| Grade 3 | <1 | 0 |
| Asthenia | ||
| Any | 74 | 75 |
| All severe or life-threatening events | 12 | 14 |
| Nail Disorder | ||
| Any | 14 | <1 |
| All severe events | <1 | 0 |
| Myalgia | ||
| Any | 18 | 12 |
| All severe events | <1 | <1 |
| Docetaxel 75 mg/m 2every 3 weeks + prednisone 5 mg twice daily n=332 % | Mitoxantrone 12 mg/m 2every 3 weeks + prednisone 5 mg twice daily n=335 % | |||
|---|---|---|---|---|
| Adverse Reaction | Any | Grade 3/4 | Any | Grade 3/4 |
| Anemia | 67 | 5 | 58 | 2 |
| Neutropenia | 41 | 32 | 48 | 22 |
| Thrombocytopenia | 3 | 1 | 8 | 1 |
| Febrile neutropenia | 3 | N/A | 2 | N/A |
| Infection | 32 | 6 | 20 | 4 |
| Epistaxis | 6 | 0 | 2 | 0 |
| Allergic Reactions | 8 | 1 | 1 | 0 |
| Fluid RetentionRelated to treatment | 24 | 1 | 5 | 0 |
| Weight Gain | 8 | 0 | 3 | 0 |
| Peripheral Edema | 18 | 0 | 2 | 0 |
| Neuropathy Sensory | 30 | 2 | 7 | 0 |
| Neuropathy Motor | 7 | 2 | 3 | 1 |
| Rash/Desquamation | 6 | 0 | 3 | 1 |
| Alopecia | 65 | N/A | 13 | N/A |
| Nail Changes | 30 | 0 | 8 | 0 |
| Nausea | 41 | 3 | 36 | 2 |
| Diarrhea | 32 | 2 | 10 | 1 |
| Stomatitis/Pharyngitis | 20 | 1 | 8 | 0 |
| Taste Disturbance | 18 | 0 | 7 | 0 |
| Vomiting | 17 | 2 | 14 | 2 |
| Anorexia | 17 | 1 | 14 | 0 |
| Cough | 12 | 0 | 8 | 0 |
| Dyspnea | 15 | 3 | 9 | 1 |
| Cardiac left ventricular function | 10 | 0 | 22 | 1 |
| Fatigue | 53 | 5 | 35 | 5 |
| Myalgia | 15 | 0 | 13 | 1 |
| Tearing | 10 | 1 | 2 | 0 |
| Arthralgia | 8 | 1 | 5 | 1 |
| Docetaxel 75 mg/m 2+ cisplatin 75 mg/m 2+ fluorouracil 750 mg/m 2 n=221 | Cisplatin 100 mg/m 2+ fluorouracil 1000 mg/m 2 n=224 | |||
|---|---|---|---|---|
| Adverse Reaction | Any % | Grade 3/4 % | Any % | Grade 3/4 % |
| Clinically important treatment-emergent adverse reactions were determined based upon frequency, severity, and clinical impact of the adverse reaction. | ||||
| Anemia | 97 | 18 | 93 | 26 |
| Neutropenia | 96 | 82 | 83 | 57 |
| Fever in the absence of infection | 36 | 2 | 23 | 1 |
| Thrombocytopenia | 26 | 8 | 39 | 14 |
| Infection | 29 | 16 | 23 | 10 |
| Febrile neutropenia | 16 | N/A | 5 | N/A |
| Neutropenic infection | 16 | N/A | 10 | N/A |
| Allergic reactions | 10 | 2 | 6 | 0 |
| Fluid retentionRelated to treatment | 15 | 0 | 4 | 0 |
| Edema | 13 | 0 | 3 | 0 |
| Lethargy | 63 | 21 | 58 | 18 |
| Neurosensory | 38 | 8 | 25 | 3 |
| Neuromotor | 9 | 3 | 8 | 3 |
| Dizziness | 16 | 5 | 8 | 2 |
| Alopecia | 67 | 5 | 41 | 1 |
| Rash/itch | 12 | 1 | 9 | 0 |
| Nail changes | 8 | 0 | 0 | 0 |
| Skin desquamation | 2 | 0 | 0 | 0 |
| Nausea | 73 | 16 | 76 | 19 |
| Vomiting | 67 | 15 | 73 | 19 |
| Anorexia | 51 | 13 | 54 | 12 |
| Stomatitis | 59 | 21 | 61 | 27 |
| Diarrhea | 78 | 20 | 50 | 8 |
| Constipation | 25 | 2 | 34 | 3 |
| Esophagitis/dysphagia/odynophagia | 16 | 2 | 14 | 5 |
| Gastrointestinal pain/cramping | 11 | 2 | 7 | 3 |
| Cardiac dysrhythmias | 5 | 2 | 2 | 1 |
| Myocardial ischemia | 1 | 0 | 3 | 2 |
| Tearing | 8 | 0 | 2 | 0 |
| Altered hearing | 6 | 0 | 13 | 2 |
| TAX323 (n=355) | TAX324 (n=494) | |||||||
|---|---|---|---|---|---|---|---|---|
| Docetaxel arm (n=174) | Comparator arm (n=181) | Docetaxel arm (n=251) | Comparator arm (n=243) | |||||
| Adverse Reaction (by Body System) | Any % | Grade 3/4 % | Any % | Grade 3/4 % | Any % | Grade 3/4 % | Any % | Grade 3/4 % |
| Clinically important treatment-emergent adverse reactions based upon frequency, severity, and clinical impact. | ||||||||
| Neutropenia | 93 | 76 | 87 | 53 | 95 | 84 | 84 | 56 |
| Anemia | 89 | 9 | 88 | 14 | 90 | 12 | 86 | 10 |
| Thrombocytopenia | 24 | 5 | 47 | 18 | 28 | 4 | 31 | 11 |
| Infection | 27 | 9 | 26 | 8 | 23 | 6 | 28 | 5 |
| Febrile neutropeniaFebrile neutropenia: grade ≥2 fever concomitant with grade 4 neutropenia requiring intravenous antibiotics and/or hospitalization. | 5 | N/A | 2 | N/A | 12 | N/A | 7 | N/A |
| Neutropenic infection | 14 | N/A | 8 | N/A | 12 | N/A | 8 | N/A |
| Cancer pain | 21 | 5 | 16 | 3 | 17 | 9 | 20 | 11 |
| Lethargy | 41 | 3 | 38 | 3 | 61 | 5 | 56 | 10 |
| Fever in the absence of infection | 32 | 1 | 37 | 0 | 30 | 4 | 28 | 3 |
| Myalgia | 10 | 1 | 7 | 0 | 7 | 0 | 7 | 2 |
| Weight loss | 21 | 1 | 27 | 1 | 14 | 2 | 14 | 2 |
| Allergy | 6 | 0 | 3 | 0 | 2 | 0 | 0 | 0 |
| Fluid retentionRelated to treatment. Edema only Weight gain only | 20 13 6 | 0 0 0 | 14 7 6 | 1 0 0 | 13 12 0 | 1 1 0 | 7 6 1 | 2 1 0 |
| Dizziness | 2 | 0 | 5 | 1 | 16 | 4 | 15 | 2 |
| Neurosensory | 18 | 1 | 11 | 1 | 14 | 1 | 14 | 0 |
| Altered hearing | 6 | 0 | 10 | 3 | 13 | 1 | 19 | 3 |
| Neuromotor | 2 | 1 | 4 | 1 | 9 | 0 | 10 | 2 |
| Alopecia | 81 | 11 | 43 | 0 | 68 | 4 | 44 | 1 |
| Rash/itch | 12 | 0 | 6 | 0 | 20 | 0 | 16 | 1 |
| Dry skin | 6 | 0 | 2 | 0 | 5 | 0 | 3 | 0 |
| Desquamation | 4 | 1 | 6 | 0 | 2 | 0 | 5 | 0 |
| Nausea | 47 | 1 | 51 | 7 | 77 | 14 | 80 | 14 |
| Stomatitis | 43 | 4 | 47 | 11 | 66 | 21 | 68 | 27 |
| Vomiting | 26 | 1 | 39 | 5 | 56 | 8 | 63 | 10 |
| Diarrhea | 33 | 3 | 24 | 4 | 48 | 7 | 40 | 3 |
| Constipation | 17 | 1 | 16 | 1 | 27 | 1 | 38 | 1 |
| Anorexia | 16 | 1 | 25 | 3 | 40 | 12 | 34 | 12 |
| Esophagitis/dysphagia/ Odynophagia | 13 | 1 | 18 | 3 | 25 | 13 | 26 | 10 |
| Taste, sense of smell altered | 10 | 0 | 5 | 0 | 20 | 0 | 17 | 1 |
| Gastrointestinal pain/cramping | 8 | 1 | 9 | 1 | 15 | 5 | 10 | 2 |
| Heartburn | 6 | 0 | 6 | 0 | 13 | 2 | 13 | 1 |
| Gastrointestinal bleeding | 4 | 2 | 0 | 0 | 5 | 1 | 2 | 1 |
| Cardiac dysrhythmia | 2 | 2 | 2 | 1 | 6 | 3 | 5 | 3 |
| VenousIncludes superficial and deep vein thrombosis and pulmonary embolism | 3 | 2 | 6 | 2 | 4 | 2 | 5 | 4 |
| Ischemia myocardial | 2 | 2 | 1 | 0 | 2 | 1 | 1 | 1 |
| Tearing | 2 | 0 | 1 | 0 | 2 | 0 | 2 | 0 |
| Conjunctivitis | 1 | 0 | 1 | 0 | 1 | 0 | 0.4 | 0 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on findings in animal reproduction studies and its mechanism of action, docetaxel can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. Available data from case reports in the literature and pharmacovigilance with docetaxel use in pregnant women are not sufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Docetaxel contains alcohol which can interfere with neurobehavioral development [see Clinical Considerations]. In animal reproductive studies, administration of docetaxel to pregnant rats and rabbits during the period of organogenesis caused an increased incidence of embryo-fetal toxicities, including intrauterine mortality, at doses as low as 0.02 and 0.003 times the recommended human dose based on body surface area, respectively [see Data].
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, miscarriage, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations Docetaxel contains alcohol [see Warnings and Precautions (5.13)]. Published studies have demonstrated that alcohol is associated with fetal harm including central nervous system abnormalities, behavioral disorders, and impaired intellectual development. Data Animal data Intravenous administration of ≥0.3 and 0.03 mg/kg/day docetaxel to pregnant rats and rabbits, respectively, during the period of organogenesis caused an increased incidence of intrauterine mortality, resorptions, reduced fetal weights, and fetal ossification delays.
Maternal toxicity was also observed at these doses, which were approximately 0.02 and 0.003 times the daily maximum recommended human dose based on body surface area, respectively.
Mechanism of action
12.1 Mechanism of Action Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, which results in the inhibition of mitosis in cells. Docetaxel's binding to microtubules does not alter the number of protofilaments in the bound microtubules, a feature which differs from most spindle poisons currently in clinical use.
US FDA labelPharmacokinetics
Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
Excretion In three cancer patients urinary and fecal excretion accounted for approximately 6% and 75% of the administered radioactivity, respectively, within 7 days.
About 80% of the radioactivity recovered in feces was excreted during the first 48 hours as 1 major and 3 minor metabolites with less than 8% as unchanged drug.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption The pharmacokinetics of docetaxel has been evaluated in cancer patients after administration of 20 mg/m 2 to 115 mg/m 2 in phase 1 studies. The area under the curve (AUC) was dose proportional following doses of 70 mg/m 2 to 115 mg/m 2 with infusion times of 1 to 2 hours. Docetaxel's pharmacokinetic profile is consistent with a three-compartment pharmacokinetic model, with initial rapid distribution phase and the late (terminal) phase.
Distribution Mean steady state volume of distribution was 113 L. Docetaxel is approximately 94% protein bound in vitro, mainly to α 1 -acid glycoprotein, albumin, and lipoproteins. In three cancer patients, the in vitro binding to plasma proteins was approximately 97%. Dexamethasone does not affect the protein binding of docetaxel.
Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135). Metabolism Docetaxel is metabolized by the CYP3A4 isoenzyme in vitro [see Drug Interactions (7)].
Excretion In three cancer patients urinary and fecal excretion accounted for approximately 6% and 75% of the administered radioactivity, respectively, within 7 days. About 80% of the radioactivity recovered in feces was excreted during the first 48 hours as 1 major and 3 minor metabolites with less than 8% as unchanged drug.
Specific Populations Effect of Age: A population pharmacokinetic analysis was carried out after docetaxel treatment of 535 patients dosed at 100 mg/m 2. Pharmacokinetic parameters estimated by this analysis were very close to those estimated from phase 1 studies. The pharmacokinetics of docetaxel was not influenced by age.
Effect of Gender: The population pharmacokinetics analysis described above also indicated that gender did not influence the pharmacokinetics of docetaxel. Hepatic Impairment: The population pharmacokinetic analysis described above indicated that in patients with clinical chemistry data suggestive of mild to moderate liver impairment (AST and/or ALT >1.5 times ULN concomitant with alkaline phosphatase >2.5 times ULN), total body clearance was lowered by an average of 27%, resulting in a 38% increase in systemic exposure (AUC).
This average, however, includes a substantial range and there is, at present, no measurement that would allow recommendation for dose adjustment in such patients. Patients with combined abnormalities of transaminase and alkaline phosphatase should not be treated with docetaxel. Patients with severe hepatic impairment have not been studied [see Warnings and Precautions (5.2), Use in Specific Populations (8.6)].
Effect of Race: Mean total body clearance for Japanese patients dosed at the range of 10 mg/m 2 to 90 mg/m 2 was similar to that of European/American populations dosed at 100 mg/m 2, suggesting no significant difference in the elimination of docetaxel in the two populations. Drug Interaction Studies Effect of Ketoconazole: The effect of ketoconazole (a strong CYP3A4 inhibitor) on the pharmacokinetics of docetaxel was investigated in 7 cancer patients.
Patients were randomized to receive either docetaxel (100 mg/m 2 intravenous) alone or docetaxel (10 mg/m 2 intravenous) in combination with ketoconazole (200 mg orally once daily for 3 days) in a crossover design with a 3-week washout period. The results of this study indicated that the mean dose-normalized AUC of docetaxel was increased 2.2-fold and its clearance was reduced by 49% when docetaxel was coadministered with ketoconazole [see Dosage and Administration (2.7), Drug Interactions (7)].
Effect of combination therapies Dexamethasone: Docetaxel total body clearance was not modified by pretreatment with dexamethasone. Cisplatin: Clearance of docetaxel in combination therapy with cisplatin was similar to that previously observed following monotherapy with docetaxel. The pharmacokinetic profile of cisplatin in combination therapy with docetaxel was similar to that observed with cisplatin alone.
Cisplatin and Fluorouracil: The combined administration of docetaxel, cisplatin and fluorouracil in 12 patients with solid tumors had no influence on the pharmacokinetics of each individual drug. Prednisone: A population pharmacokinetic analysis of plasma data from 40 patients with metastatic castration-resistant prostate cancer indicated that docetaxel systemic clearance in combination with prednisone is similar to that observed following administration of docetaxel alone.
Cyclophosphamide and Doxorubicin: A study was conducted in 30 patients with advanced breast cancer to determine the potential for drug-drug interactions between docetaxel (75 mg/m 2), doxorubicin (50 mg/m 2), and cyclophosphamide (500 mg/m 2) when administered in combination. The coadministration of docetaxel had no effect on the pharmacokinetics of doxorubicin and cyclophosphamide when the three drugs were given in combination compared to coadministration of doxorubicin and cyclophosphamide only.
In addition, doxorubicin and cyclophosphamide had no effect on docetaxel plasma clearance when the three drugs were given in combination compared to historical data for docetaxel monotherapy.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Docetaxel 20 mg/0.5 mL, 0.5 mL Vial | ₱745.00–₱1,598.88Reference ₱958.00 | per vial | DPRI procurement range |
| Docetaxel 40 mg/mL, 2 mL Vial | ₱1,699.00–₱3,968.88Reference ₱3,968.88 | per vial | DPRI procurement range |
| Docetaxel 20 mg/mL, 1 mL concentrate for solution for IV infusion | ₱586.00 | per unit | DPRI reference price |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Docetaxel |
| PNF listing | Inj.: 10 mg/mL solution for infusion (IV), 2 mL and 8 mL vialRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 20 mg/0.5 mL, 0.5 mL vial (IV infusion) (anhydrous)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 40 mg/mL, 2 mL vial (IV infusion) (anhydrous)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 20 mg/mL, 1mL concentrate for solution for IV infusion (as trihydrate)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 80 mg/4mL, 4 mL concentrate for solution for IV infusion (as trihydrate)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Docetaxel · Sanofi-Aventis U.S. LLC [US FDA-approved label, version 30, December 6, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
